

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/31, C07K 14/24, C12N 1/21, 1/19, 5/10, A01H 5/00	A1	(11) International Publication Number: WO 99/54472 (43) International Publication Date: 28 October 1999 (28.10.99)
(21) International Application Number: PCT/EP99/02629 (22) International Filing Date: 19 April 1999 (19.04.99) (30) Priority Data: 09/063,982 21 April 1998 (21.04.98) US 60/123,500 9 March 1999 (09.03.99) US (71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT). (72) Inventors; and (75) Inventors/Applicants (for US only): KRAMER, Vance, Cary [US/US]; 608 Dana Court, Hillsborough, NC 27278 (US). MORGAN, Michael, Kent [US/US]; 5805 Garrett Road, Durham, NC 27707 (US). ANDERSON, Arne, Robert [US/US]; 1005 Green-Pace Road, Zebulon, NC 27597 (US). (74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <i>With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.</i>	
(54) Title: NOVEL INSECTICIDAL TOXINS FROM <i>XENORHABDUS NEMATOPHILUS</i> AND NUCLEIC ACID SEQUENCES CODING THEREFOR		
(57) Abstract Novel nucleic acid sequences isolated from <i>Xenorhabdus nematophilus</i> , <i>Xenorhabdus poinarii</i> , and <i>Photorhabdus luminescens</i> , whose expression results in novel insecticidal toxins, are disclosed herein. The invention also discloses compositions and formulations containing the insecticidal toxins that are capable of controlling insect pests. The invention is further drawn to methods of making the toxins and to methods of using the nucleotide sequences, for example in microorganisms to control insect pests or in transgenic plants to confer insect resistance.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**NOVEL INSECTICIDAL TOXINS FROM *XENORHABDUS NEMATOPHILUS* AND
NUCLEIC ACID SEQUENCES CODING THEREFOR**

The invention relates to novel toxins from *Xenorhabdus nematophilus*, *Xenorhabdus poinarii*, and *Photorhabdus luminescens*, nucleic acid sequences whose expression results in said toxins, and methods of making and methods of using the toxins and corresponding nucleic acid sequences to control insects.

Insect pests are a major cause of crop losses. Solely in the US, about \$7.7 billion are lost every year due to infestation by various genera of insects. In addition to losses in field crops, insect pests are also a burden to vegetable and fruit growers, to producers of ornamental flowers, and they are a nuisance to gardeners and home owners.

Insect pests are mainly controlled by intensive applications of chemical insecticides, which are active through inhibition of insect growth, prevention of insect feeding or reproduction, or death of the insects. Good insect control can thus be reached, but these chemicals can sometimes also affect other, beneficial insects. Another problem resulting from the wide use of chemical pesticides is the appearance of resistant insect varieties. This has been partially alleviated by various resistance management strategies, but there is an increasing need for alternative pest control agents. Biological insect control agents, such as *Bacillus thuringiensis* strains expressing insecticidal toxins like δ -endotoxins, have also been applied with satisfactory results, offering an alternative or a complement to chemical insecticides. Recently, the genes coding for some of these δ -endotoxins have been isolated and their expression in heterologous hosts have been shown to provide another tool for the control of economically important insect pests. In particular, the expression of insecticidal toxins in transgenic plants, such as *Bacillus thuringiensis* δ -endotoxins, has provided efficient protection against selected insect pests, and transgenic plants expressing such toxins have been commercialized, allowing farmers to reduce applications of chemical insect control agents. Yet, even in this case, the development of resistance remains a possibility and only a few specific insect pests are controllable. Consequently, there remains a long-felt but unfulfilled need to discover new and effective insect control agents that provide an economic benefit to farmers and that are environmentally acceptable.

The present invention addresses the long-standing need for novel insect control agents. Particularly needed are control agents that are targeted to economically important insect pests and that efficiently control insect strains resistant to existing insect control agents. Furthermore, agents whose application minimizes the burden on the environment are desirable.

In the search for novel insect control agents, certain classes of nematodes from the genera *Heterorhabdus* and *Steinernema* are of particular interest because of their insecticidal properties. They kill insect larvae and their offspring feed in the dead larvae. Indeed, the insecticidal activity is due to symbiotic bacteria living in the nematodes. These symbiotic bacteria are *Photorhabdus* in the case of *Heterorhabdus* and *Xenorhabdus* in the case of *Steinernema*.

The present invention is drawn to nucleotide sequences isolated from *Xenorhabdus nematophilus*, and nucleotide sequences substantially similar thereto, whose expression result in insecticidal toxins that are highly toxic to economically important pests, particularly plant pests. The invention is further drawn to the insecticidal toxin resulting from the expression of the nucleotide sequence, and to compositions and formulations containing the insecticidal toxin, that are capable of inhibiting the ability of insect pests to survive, grow or reproduce, or of limiting insect-related damage or loss in crop plants. The invention is further drawn to a method of making the toxin and to methods of using the nucleotide sequence, for example in microorganisms to control insects or in transgenic plants to confer insect resistance, and to a method of using the toxin, and compositions and formulations comprising the toxin, for example applying the toxin, composition or formulation to insect infested areas, or to prophylactically treat insect susceptible areas or plants to confer protection or resistance against harmful insects.

The novel toxin is highly insecticidal against *Plutella xylostella* (diamondback moth), an economically important insect pest. The toxin can be used in multiple insect control strategies, resulting in maximal efficiency with minimal impact on the environment.

According to one aspect, the present invention provides an isolated nucleic acid molecule comprising: (a) a nucleotide sequence substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:14; or (b) a nucleotide sequence isocoding with the nucleotide sequence of (a); wherein expression of said nucleic acid molecule results in

at least one toxin that is active against insects. In one embodiment of this aspect, the nucleotide sequence is isocoding with a nucleotide sequence substantially similar to nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14. Preferably, the nucleotide sequence is substantially similar to nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14. More preferably, the nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 3, 5, 7, 9, 11, 13, and 15. Most preferably, the nucleotide sequence comprises nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14. In another embodiment, the nucleotide sequence comprises the approximately 3.0 kb DNA fragment comprised in pCIB9369 (NRRL B-21883).

According to a preferred embodiment, the toxins resulting from expression of the nucleic acid molecules of the invention have activity against *Plutella xylostella*.

In another aspect, the present invention provides an isolated nucleic acid molecule comprising a 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion of a nucleotide sequence selected from the group consisting of: nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:14, wherein expression of said nucleic acid molecule results in at least one toxin that is active against insects.

The present invention also provides a chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule of the invention. Further, the present invention provides a recombinant vector comprising such a chimeric gene. Still further, the present invention provides a host cell comprising such a chimeric gene. A host cell according to this aspect of the invention may be a bacterial cell, a yeast cell, or a plant cell, preferably a plant cell. Even further, the present invention provides a plant comprising such a plant cell. Preferably, the plant is maize.

In yet another aspect, the present invention provides toxins produced by the expression of DNA molecules of the present invention. According to a preferred embodiment, the toxins of the invention have activity against *Plutella xylostella*.

In one embodiment, the toxins are produced by the *E. coli* strain designated as NRRL accession number B-21883.

In another embodiment, a toxin of the invention comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs:2, 3, 5, 7, 9, 11, 13, and 15.

Also provided is a composition comprising an insecticidally effective amount of a toxin of the invention. In another aspect, the present invention provides a method of producing a toxin that is active against insects, comprising: (a) obtaining a host cell comprising a chimeric gene, which itself comprises a heterologous promoter sequence operatively linked to the nucleic acid molecule of the invention; and (b) expressing the nucleic acid molecule in the cell, which results in at least one toxin that is active against insects.

In a further aspect, the present invention provides a method of producing an insect-resistant plant, comprising introducing a nucleic acid molecule of the invention into the plant, wherein the nucleic acid molecule is expressible in the plant in an effective amount to control insects. According to a preferred embodiment, the insects are *Plutella xylostella*.

In a still further aspect, the present invention provides a method of controlling insects comprising delivering to the insects an effective amount of a toxin according to the present invention. According to a preferred embodiment, the insects are *Plutella xylostella*. Preferably, the toxin is delivered to the insects orally.

Yet another aspect of the present invention is the provision of a method for mutagenizing a nucleic acid molecule according to the present invention, wherein the nucleic acid molecule has been cleaved into population of double-stranded random fragments of a desired size, comprising: (a) adding to the population of double-stranded random fragments one or more single- or double-stranded oligonucleotides, wherein the oligonucleotides each comprise an area of identity and an area of heterology to a double-stranded template polynucleotide; (b) denaturing the resultant mixture of double-stranded random fragments and oligonucleotides into single-stranded fragments; (c) incubating the resultant population of single-stranded fragments with a polymerase under conditions which result in the annealing of the single-stranded fragments at the areas of identity to form pairs of annealed fragments, the areas of identity being sufficient for one member of a pair to prime replication of the other, thereby forming a mutagenized double-stranded polynucleotide; and (d) repeating the second and third steps for at least two further cycles, wherein the resultant mixture in the second step of a further cycle includes the mutagenized double-stranded polynucleotide from the third step of the previous cycle, and wherein the further cycle forms a further mutagenized double-stranded polynucleotide.

Other aspects and advantages of the present invention will become apparent to those skilled in the art from a study of the description of the invention and non-limiting examples.

DEFINITIONS

Activity" of the toxins of the invention is meant that the toxins function as orally active insect control agents, have a toxic effect, or are able to disrupt or deter insect feeding, which may or may not cause death of the insect. When a toxin of the invention is delivered to the insect, the result is typically death of the insect, or the insect does not feed upon the source that makes the toxin available to the insect.

"Associated with / operatively linked" refer to two nucleic acid sequences that are related physically or functionally. For example, a promoter or regulatory DNA sequence is said to be "associated with" a DNA sequence that codes for an RNA or a protein if the two sequences are operatively linked, or situated such that the regulator DNA sequence will affect the expression level of the coding or structural DNA sequence.

A "chimeric gene" is a recombinant nucleic acid sequence in which a promoter or regulatory nucleic acid sequence is operatively linked to, or associated with, a nucleic acid sequence that codes for an mRNA or which is expressed as a protein, such that the regulator nucleic acid sequence is able to regulate transcription or expression of the associated nucleic acid sequence. The regulator nucleic acid sequence of the chimeric gene is not normally operatively linked to the associated nucleic acid sequence as found in nature.

A "coding sequence" is a nucleic acid sequence that is transcribed into RNA such as mRNA, rRNA, tRNA, snRNA, sense RNA or antisense RNA. Preferably the RNA is then translated in an organism to produce a protein.

To "control" insects means to inhibit, through a toxic effect, the ability of insect pests to survive, grow, feed, and/or reproduce, or to limit insect-related damage or loss in crop plants. To "control" insects may or may not mean killing the insects, although it preferably means killing the insects.

To "deliver" a toxin means that the toxin comes in contact with an insect, resulting in toxic effect and control of the insect. The toxin can be delivered in many recognized ways, e.g., orally by ingestion by the insect or by contact with the insect via transgenic plant expression, formulated protein composition(s), sprayable protein composition(s), a bait matrix, or any other art-recognized toxin delivery system.

"Expression cassette" as used herein means a nucleic acid sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operably linked to the nucleotide sequence of interest which is operably linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The expression cassette comprising the nucleotide sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression cassette may also be one which is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host, i.e., the particular nucleic acid sequence of the expression cassette does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, such as a plant, the promoter can also be specific to a particular tissue, or organ, or stage of development.

A "gene" is a defined region that is located within a genome and that, besides the aforementioned coding nucleic acid sequence, comprises other, primarily regulatory, nucleic acid sequences responsible for the control of the expression, that is to say the transcription and translation, of the coding portion. A gene may also comprise other 5' and 3' untranslated sequences and termination sequences. Further elements that may be present are, for example, introns.

"Gene of interest" refers to any gene which, when transferred to a plant, confers upon the plant a desired characteristic such as antibiotic resistance, virus resistance, insect resistance, disease resistance, or resistance to other pests, herbicide tolerance, improved nutritional value, improved performance in an industrial process or altered reproductive capability. The "gene of interest" may also be one that is transferred to plants for the production of commercially valuable enzymes or metabolites in the plant.

A "heterologous" nucleic acid sequence is a nucleic acid sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring nucleic acid sequence.

A "homologous" nucleic acid sequence is a nucleic acid sequence naturally associated with a host cell into which it is introduced.

"Homologous recombination" is the reciprocal exchange of nucleic acid fragments between homologous nucleic acid molecules.

"Insecticidal" is defined as a toxic biological activity capable of controlling insects, preferably by killing them.

A nucleic acid sequence is "isocoding with" a reference nucleic acid sequence when the nucleic acid sequence encodes a polypeptide having the same amino acid sequence as the polypeptide encoded by the reference nucleic acid sequence.

An "isolated" nucleic acid molecule or an isolated enzyme is a nucleic acid molecule or enzyme that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule or enzyme may exist in a purified form or may exist in a non-native environment such as, for example, a recombinant host cell.

A "nucleic acid molecule" or "nucleic acid sequence" is a linear segment of single- or double-stranded DNA or RNA that can be isolated from any source. In the context of the present invention, the nucleic acid molecule is preferably a segment of DNA.

"ORF" means open reading frame.

A "plant" is any plant at any stage of development, particularly a seed plant.

A "plant cell" is a structural and physiological unit of a plant, comprising a protoplast and a cell wall. The plant cell may be in form of an isolated single cell or a cultured cell, or as a part of higher organized unit such as, for example, plant tissue, a plant organ, or a whole plant.

"Plant cell culture" means cultures of plant units such as, for example, protoplasts, cell culture cells, cells in plant tissues, pollen, pollen tubes, ovules, embryo sacs, zygotes and embryos at various stages of development.

"Plant material" refers to leaves, stems, roots, flowers or flower parts, fruits, pollen, egg cells, zygotes, seeds, cuttings, cell or tissue cultures, or any other part or product of a plant.

A "plant organ" is a distinct and visibly structured and differentiated part of a plant such as a root, stem, leaf, flower bud, or embryo.

"Plant tissue" as used herein means a group of plant cells organized into a structural and functional unit. Any tissue of a plant *in planta* or in culture is included. This term includes, but is not limited to, whole plants, plant organs, plant seeds, tissue culture and any groups of plant cells organized into structural and/or functional units. The use of this term in conjunction with, or in the absence of, any specific type of plant tissue as listed

above or otherwise embraced by this definition is not intended to be exclusive of any other type of plant tissue.

A "promoter" is an untranslated DNA sequence upstream of the coding region that contains the binding site for RNA polymerase II and initiates transcription of the DNA. The promoter region may also include other elements that act as regulators of gene expression.

A "protoplast" is an isolated plant cell without a cell wall or with only parts of the cell wall.

"Regulatory elements" refer to sequences involved in controlling the expression of a nucleotide sequence. Regulatory elements comprise a promoter operably linked to the nucleotide sequence of interest and termination signals. They also typically encompass sequences required for proper translation of the nucleotide sequence.

In its broadest sense, the term "substantially similar", when used herein with respect to a nucleotide sequence, means a nucleotide sequence corresponding to a reference nucleotide sequence, wherein the corresponding sequence encodes a polypeptide having substantially the same structure and function as the polypeptide encoded by the reference nucleotide sequence, e.g. where only changes in amino acids not affecting the polypeptide function occur. Desirably the substantially similar nucleotide sequence encodes the polypeptide encoded by the reference nucleotide sequence. The percentage of identity between the substantially similar nucleotide sequence and the reference nucleotide sequence desirably is at least 80%, more desirably at least 85%, preferably at least 90%, more preferably at least 95%, still more preferably at least 99%. A nucleotide sequence "substantially similar" to reference nucleotide sequence hybridizes to the reference nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 2X SSC, 0.1% SDS at 50°C, more desirably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 1X SSC, 0.1% SDS at 50°C, more desirably still in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 0.5X SSC, 0.1% SDS at 50°C, preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 0.1X SSC, 0.1% SDS at 50°C, more preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄, 1 mM EDTA at 50°C with washing in 0.1X SSC, 0.1% SDS at 65°C.

"Synthetic" refers to a nucleotide sequence comprising structural characters that are not present in the natural sequence. For example, an artificial sequence that resembles more closely the G+C content and the normal codon distribution of dicot and/or monocot genes is said to be synthetic.

"Transformation" is a process for introducing heterologous nucleic acid into a host cell or organism. In particular, "transformation" means the stable integration of a DNA molecule into the genome of an organism of interest.

"Transformed / transgenic / recombinant" refer to a host organism such as a bacterium or a plant into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can be auto-replicating. Transformed cells, tissues, or plants are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof. A "non-transformed", "non-transgenic", or "non-recombinant" host refers to a wild-type organism, e.g., a bacterium or plant, which does not contain the heterologous nucleic acid molecule.

Nucleotides are indicated by their bases by the following standard abbreviations: adenine (A), cytosine (C), thymine (T), and guanine (G). Amino acids are likewise indicated by the following standard abbreviations: alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C), glutamine (Gln; Q), glutamic acid (Glu; E), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V). Furthermore, (Xaa; X) represents any amino acid.

BRIEF DESCRIPTION OF THE SEQUENCES IN THE SEQUENCE LISTING

SEQ ID NO:1 is the sequence of the approximately 3.0 kb DNA fragment comprised in *Xenorhabdus nematophilus* clone pCIB9369, which comprises the following ORFs at the specified nucleotide positions:

<u>Name</u>	<u>Start</u>	<u>End</u>
orf1	569	979
orf2	1045	2334

SEQ ID NO:2 is the sequence of the ~15 kDa protein encoded by orf1 of clone pCIB9369.

SEQ ID NO:3 is the sequence of the ~47.7 kDa Juvenile Hormone Esterase-like protein encoded by orf2 of clone pCIB9369.

SEQ ID NO:4 is the DNA sequence of orf1 of *Xenorhabdus nematophilus* clone pCIB9381.

SEQ ID NO:5 is the sequence of the protein encoded by orf1 of clone pCIB9381.

SEQ ID NO:6 is the DNA sequence of orf2 of *Xenorhabdus nematophilus* clone pCIB9381.
SEQ ID NO:7 is the sequence of the Juvenile Hormone Esterase-like protein encoded by orf2 of clone pCIB9381.
SEQ ID NO:8 is the DNA sequence of orf1 of *Xenorhabdus poinarii* clone pCIB9354.
SEQ ID NO:9 is the sequence of the protein encoded by orf1 of clone pCIB9354.
SEQ ID NO:10 is the DNA sequence of orf2 of *Xenorhabdus poinarii* clone pCIB9354.
SEQ ID NO:11 is the sequence of the Juvenile Hormone Esterase-like protein encoded by orf2 of clone pCIB9354.
SEQ ID NO:12 is the DNA sequence of orf1 of *Photorhabdus luminescens* clone pCIB9383-21.
SEQ ID NO:13 is the sequence of the protein encoded by orf1 of clone pCIB9383-21.
SEQ ID NO:14 is the DNA sequence of orf2 of *Photorhabdus luminescens* clone pCIB9383-21.
SEQ ID NO:15 is the sequence of the Juvenile Hormone Esterase-like protein encoded by orf2 of clone pCIB9383-21.

DEPOSITS

The following material has been deposited with the Agricultural Research Service, Patent Culture Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604, under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. All restrictions on the availability of the deposited material will be irrevocably removed upon the granting of a patent.

<u>Clone</u>	<u>Accession Number</u>	<u>Date of Deposit</u>
pCIB9369	NRRL B-21883	November 12, 1997
pCIB9354	NRRL B-30109	February 25, 1999
pCIB9381	NRRL B-30110	February 25, 1999
pCIB9383-21	NRRL B-30111	February 25, 1999

Novel Nucleic Acid Sequences whose Expression Results in Insecticidal Toxins

This invention relates to nucleic acid sequences whose expression results in novel toxins, and to the making and using of the toxins to control insect pests. The nucleic acid sequences are isolated from *Xenorhabdus nematophilus*, *Xenorhabdus poinarii*, and *Photorhabdus luminescens*, members of the *Enterobacteriaceae* family. *Xenorhabdus* are symbiotic bacteria of nematodes of the genus *Steinernema*. *Photorhabdus* are symbiotic

bacteria of nematodes of the genus *Heterorhabditis*. The nematodes colonize insect larva, kill them, and their offspring feed on the dead larvae. The insecticidal activity is actually produced by the symbiotic *Xenorhabdus* and *Photorhabdus* bacteria. The inventors are the first to isolate the nucleic acid sequences of the present invention. The expression of the nucleic acid sequences of the present invention results in toxins that can be used to control Lepidopteran insects such as *Plutella xylostella* (Diamondback Moth).

A nucleotide sequence of the present invention in clone pCIB9369 is characterized by an approximately 3.0 kb DNA fragment deposited pursuant to the Budapest Treaty for Patent Deposits under Accession Number NRRL B-21883. The sequence of this DNA fragment is set forth in SEQ ID NO:1. Two open reading frames (ORF) are present in SEQ ID NO:1 (nucleotides 569-979 and nucleotides 1045-2334, respectively), coding for proteins of predicted sizes of 15 kDa and 47.7 kDa (SEQ ID NOs:2 and 3, respectively). The two ORFs are arranged in an operon-like structure. A search for known sequences showing homology to each individual ORF using the UWGCG Blast and Gap programs does not reveal any significant match for ORF #1 and reveals 21% identity between ORF #2 and *Bacillus thuringiensis* cry3A protein, which is not considered to be significant in the art. A Gap analysis of the protein encoded by ORF #2 of pCIB9369 by the Blast program identifies 30.6% AA identity and 44.1% AA similarity to a juvenile hormone esterase-related protein (GenBank accession 2921553; Henikoff et al., *PNAS USA* 89: 10915-10919 (1992)). The nucleotide sequence of the present invention is also compared to known *Xenorhabdus nematophilus* sequences encoding the insecticidal toxin toxb4 (WO 95/00647), but no significant homology is found. The 3.0 kb DNA fragment is also compared to the nucleotide sequence published in WO 98/08388. Twenty-two sequences of 60 nucleotides each (60-mers) from the 38.2 kb DNA fragment described in WO 98/08388 are compared to the 3.0 kb DNA fragment of the present invention using the UWGCG Gap program. The nucleotide sequence of the first 60-mer starts at base 1 of the 38.2 kb DNA fragment and the other 60-mers are located at approximately 2.0 kb intervals. Each of the 22 sequences as well as their complementary sequences are tested. The highest percent of identity between the 3.0 kb DNA fragment of the present invention and one of these 60-mers is 53%, which is not a significant homology. Furthermore, five different DNA fragments of the 38.2 kb sequence are tested for hybridization to the 3.0 kb fragment of the present invention by Southern blot analysis. None of them reveal a positive hybridization signal.

The nucleotide sequences of pCIB9381, pCIB9354, and pCIB9383-21 also reveal two open reading frames in each of these clones. The nucleotide sequences of the two ORFs in each of pCIB9381 and pCIB9383-21 are highly homologous to those in pCIB9369. Hence, the ORF #2 proteins of pCIB9381 and pCIB9383-21 have essentially the same homology to the juvenile hormone esterase-related protein as does the ORF #2 protein of pCIB9369. The nucleotide sequence of ORF #1 of pCIB9354 is 77% identical to the nucleotide sequence of ORF #1 of pCIB9369, and the nucleotide sequence of ORF #2 of pCIB9354 is 79% identical to the nucleotide sequence of ORF #2 of pCIB9369. The ORF #2 protein of pCIB9354 also has homology to the juvenile hormone esterase-related protein (29.2% AA identity and 42.2% AA similarity).

In a preferred embodiment, the invention encompasses a nucleotide sequence substantially similar to nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:14, whose expression results in an insecticidal toxin. The present invention also encompasses recombinant vectors comprising the nucleic acid sequences of this invention. In such vectors, the nucleic acid sequences are preferably comprised in expression cassettes comprising regulatory elements for expression of the nucleotide sequences in a host cell capable of expressing the nucleotide sequences. Such regulatory elements usually comprise promoter and termination signals and preferably also comprise elements allowing efficient translation of polypeptides encoded by the nucleic acid sequences of the present invention. Vectors comprising the nucleic acid sequences are usually capable of replication in particular host cells, preferably as extrachromosomal molecules, and are therefore used to amplify the nucleic acid sequences of this invention in the host cells. In one embodiment, host cells for such vectors are microorganisms, such as bacteria, in particular *E.coli*. In another embodiment, host cells for such recombinant vectors are endophytes or epiphytes. A preferred host cell for such vectors is a eukaryotic cell, such as a yeast, a plant cell, or an insect cell. Plant cells such as maize cells are most preferred host cells. In another preferred embodiment, such vectors are viral vectors and are used for replication of the nucleotide sequences in particular host cells, e.g. insect cells or plant cells. Recombinant vectors are also used for transformation of the nucleotide sequences of this invention into host cells, whereby the nucleotide sequences are stably integrated into the DNA of such host cells. In one, such host cells are prokaryotic cells. In a preferred embodiment, such host cells are eukaryotic cells, such as yeast cells, insect cells, or plant cells. In a most preferred embodiment, the host cells are plant cells, such as maize cells.

The nucleotide sequences of the invention can be isolated using the techniques described in the examples below, or by PCR using the sequences set forth in the sequence listing as the basis for constructing PCR primers. For example, oligonucleotides having the sequence of approximately the first and last 20-25 consecutive nucleotides of orf1 of SEQ ID NO:1 (e.g., nucleotides 569-588 and 957-976 of SEQ ID NO:1) can be used as PCR primers to amplify the orf1 coding sequence (nucleotides 569-976 of SEQ ID NO:1) directly from the source strain (*Xenorhabdus nematophilus* strain ATCC 19061). The other gene sequences of the invention can likewise be amplified by PCR from the respective source strains using the ends of the coding sequences set forth in the sequence listing as the basis for PCR primers.

In another preferred embodiment, the insecticidal toxins comprise at least one polypeptide encoded by a nucleotide sequence of the invention. The molecular weight of an insecticidal toxin according to the invention is larger than 6,000, as determined by size fractionation experiments. After treatment with proteinase K, only a minimal decrease in insecticidal activity is observed in the insect bioassay, indicating that the insecticidal toxins are substantially resistant to proteinase K treatment. The insecticidal toxins retain their insecticidal activity after being stored at 22°C or at 4°C for 2 weeks. They also retain their insecticidal activity after being freeze dried and stored at 22°C for 2 weeks. The insecticidal toxins are also still active after incubation for 5 minutes at 60°C, but they lose their insecticidal activity after incubation for 5 minutes at 100°C or 80°C.

In further embodiments, the nucleotide sequences of the invention can be modified by incorporation of random mutations in a technique known as *in-vitro* recombination or DNA shuffling. This technique is described in Stemmer et al., Nature 370: 389-391 (1994) and US Patent 5,605,793, which are incorporated herein by reference. Millions of mutant copies of a nucleotide sequence are produced based on an original nucleotide sequence of this invention and variants with improved properties, such as increased insecticidal activity, enhanced stability, or different specificity or range of target insect pests are recovered. The method encompasses forming a mutagenized double-stranded polynucleotide from a template double-stranded polynucleotide comprising a nucleotide sequence of this invention, wherein the template double-stranded polynucleotide has been cleaved into double-stranded-random fragments of a desired size, and comprises the steps of adding to the resultant population of double-stranded random fragments one or more single or double-stranded oligonucleotides, wherein said oligonucleotides comprise an area of

identity and an area of heterology to the double-stranded template polynucleotide; denaturing the resultant mixture of double-stranded random fragments and oligonucleotides into single-stranded fragments; incubating the resultant population of single-stranded fragments with a polymerase under conditions which result in the annealing of said single-stranded fragments at said areas of identity to form pairs of annealed fragments, said areas of identity being sufficient for one member of a pair to prime replication of the other, thereby forming a mutagenized double-stranded polynucleotide; and repeating the second and third steps for at least two further cycles, wherein the resultant mixture in the second step of a further cycle includes the mutagenized double-stranded polynucleotide from the third step of the previous cycle, and the further cycle forms a further mutagenized double-stranded polynucleotide. In a preferred embodiment, the concentration of a single species of double-stranded random fragment in the population of double-stranded random fragments is less than 1% by weight of the total DNA. In a further preferred embodiment, the template double-stranded polynucleotide comprises at least about 100 species of polynucleotides. In another preferred embodiment, the size of the double-stranded random fragments is from about 5 bp to 5 kb. In a further preferred embodiment, the fourth step of the method comprises repeating the second and the third steps for at least 10 cycles.

Expression of the Nucleotide Sequences in Heterologous Microbial Hosts

As biological insect control agents, the insecticidal toxins are produced by expression of the nucleotide sequences in heterologous host cells capable of expressing the nucleotide sequences. In a first embodiment, *Xenorhabdus nematophilus*, *Xenorhabdus poinarii*, or *Photorhabdus luminescens* cells comprising modifications of at least one nucleotide sequence of this invention at its chromosomal location are described. Such modifications encompass mutations or deletions of existing regulatory elements, thus leading to altered expression of the nucleotide sequence, or the incorporation of new regulatory elements controlling the expression of the nucleotide sequence. In another embodiment, additional copies of one or more of the nucleotide sequences are added to *Xenorhabdus nematophilus*, *Xenorhabdus poinarii*, or *Photorhabdus luminescens* cells either by insertion into the chromosome or by introduction of extrachromosomally replicating molecules containing the nucleotide sequences.

In another embodiment, at least one of the nucleotide sequences of the invention is inserted into an appropriate expression cassette, comprising a promoter and termination signals. Expression of the nucleotide sequence is constitutive, or an inducible promoter

responding to various types of stimuli to initiate transcription is used. In a preferred embodiment, the cell in which the toxin is expressed is a microorganism, such as a virus, a bacteria, or a fungus. In a preferred embodiment, a virus, such as a baculovirus, contains a nucleotide sequence of the invention in its genome and expresses large amounts of the corresponding insecticidal toxin after infection of appropriate eukaryotic cells that are suitable for virus replication and expression of the nucleotide sequence. The insecticidal toxin thus produced is used as an insecticidal agent. Alternatively, baculoviruses engineered to include the nucleotide sequence are used to infect insects *in-vivo* and kill them either by expression of the insecticidal toxin or by a combination of viral infection and expression of the insecticidal toxin.

Bacterial cells are also hosts for the expression of the nucleotide sequences of the invention. In a preferred embodiment, non-pathogenic symbiotic bacteria, which are able to live and replicate within plant tissues, so-called endophytes, or non-pathogenic symbiotic bacteria, which are capable of colonizing the phyllosphere or the rhizosphere, so-called epiphytes, are used. Such bacteria include bacteria of the genera *Agrobacterium*, *Alcaligenes*, *Azospirillum*, *Azotobacter*, *Bacillus*, *Clavibacter*, *Enterobacter*, *Erwinia*, *Flavobacter*, *Klebsiella*, *Pseudomonas*, *Rhizobium*, *Serratia*, *Streptomyces* and *Xanthomonas*. Symbiotic fungi, such as *Trichoderma* and *Gliocladium* are also possible hosts for expression of the inventive nucleotide sequences for the same purpose.

Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, the expression vectors pKK223-3 and pKK223-2 can be used to express heterologous genes in *E. coli*, either in transcriptional or translational fusion, behind the *tac* or *trc* promoter. For the expression of operons encoding multiple ORFs, the simplest procedure is to insert the operon into a vector such as pKK223-3 in transcriptional fusion, allowing the cognate ribosome binding site of the heterologous genes to be used. Techniques for overexpression in gram-positive species such as *Bacillus* are also known in the art and can be used in the context of this invention (Quax *et al.* *In: Industrial Microorganisms: Basic and Applied Molecular Genetics*, Eds. Baltz *et al.*, American Society for Microbiology, Washington (1993)). Alternate systems for overexpression rely for example, on yeast vectors and include the use of *Pichia*, *Saccharomyces* and *Kluyveromyces* (Sreekrishna, *In: Industrial microorganisms: basic and applied molecular genetics*, Baltz, Hegeman, and Skatrud *eds.*, American Society for

Microbiology, Washington (1993); Dequin & Barre, *Biotechnology* 12:173-177 (1994); van den Berg *et al.*, *Biotechnology* 8:135-139 (1990)).

In another preferred embodiment, at least one of the described nucleotide sequences is transferred to and expressed in *Pseudomonas fluorescens* strain CGA267356 (described in the published application EU 0 472 494 and in WO 94/01561) which has biocontrol characteristics. In another preferred embodiment, a nucleotide sequence of the invention is transferred to *Pseudomonas aureofaciens* strain 30-84 which also has biocontrol characteristics. Expression in heterologous biocontrol strains requires the selection of vectors appropriate for replication in the chosen host and a suitable choice of promoter. Techniques are well known in the art for expression in gram-negative and gram-positive bacteria and fungi.

Expression of the Nucleotide Sequences in Plant Tissue

In a particularly preferred embodiment, at least one of the insecticidal toxins of the invention is expressed in a higher organism, e.g., a plant. In this case, transgenic plants expressing effective amounts of the toxins protect themselves from insect pests. When the insect starts feeding on such a transgenic plant, it also ingests the expressed toxins. This will deter the insect from further biting into the plant tissue or may even harm or kill the insect. A nucleotide sequence of the present invention is inserted into an expression cassette, which is then preferably stably integrated in the genome of said plant. In another preferred embodiment, the nucleotide sequence is included in a non-pathogenic self-replicating virus. Plants transformed in accordance with the present invention may be monocots or dicots and include, but are not limited to, maize, wheat, barley, rye, sweet potato, bean, pea, chicory, lettuce, cabbage, cauliflower, broccoli, turnip, radish, spinach, asparagus, onion, garlic, pepper, celery, squash, pumpkin, hemp, zucchini, apple, pear, quince, melon, plum, cherry, peach, nectarine, apricot, strawberry, grape, raspberry, blackberry, pineapple, avocado, papaya, mango, banana, soybean, tomato, sorghum, sugarcane, sugarbeet, sunflower, rapeseed, clover, tobacco, carrot, cotton, alfalfa, rice, potato, eggplant, cucumber, *Arabidopsis*, and woody plants such as coniferous and deciduous trees.

Once a desired nucleotide sequence has been transformed into a particular plant species, it may be propagated in that species or moved into other varieties of the same species, particularly including commercial varieties, using traditional breeding techniques.

A nucleotide sequence of this invention is preferably expressed in transgenic plants, thus causing the biosynthesis of the corresponding toxin in the transgenic plants. In this way, transgenic plants with enhanced resistance to insects are generated. For their expression in transgenic plants, the nucleotide sequences of the invention may require modification and optimization. Although in many cases genes from microbial organisms can be expressed in plants at high levels without modification, low expression in transgenic plants may result from microbial nucleotide sequences having codons that are not preferred in plants. It is known in the art that all organisms have specific preferences for codon usage, and the codons of the nucleotide sequences described in this invention can be changed to conform with plant preferences, while maintaining the amino acids encoded thereby. Furthermore, high expression in plants is best achieved from coding sequences that have at least 35% about GC content, preferably more than about 45%, more preferably more than about 50%, and most preferably more than about 60%. Microbial nucleotide sequences which have low GC contents may express poorly in plants due to the existence of ATTTA motifs which may destabilize messages, and AATAAA motifs which may cause inappropriate polyadenylation. Although preferred gene sequences may be adequately expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledons or dicotyledons as these preferences have been shown to differ (Murray *et al.* Nucl. Acids Res. 17: 477-498 (1989)). In addition, the nucleotide sequences are screened for the existence of illegitimate splice sites that may cause message truncation. All changes required to be made within the nucleotide sequences such as those described above are made using well known techniques of site directed mutagenesis, PCR, and synthetic gene construction using the methods described in the published patent applications EP 0 385 962 (to Monsanto), EP 0 359 472 (to Lubrizol, and WO 93/07278 (to Ciba-Geigy).

For efficient initiation of translation, sequences adjacent to the initiating methionine may require modification. For example, they can be modified by the inclusion of sequences known to be effective in plants. Joshi has suggested an appropriate consensus for plants (NAR 15: 6643-6653 (1987)) and Clontech suggests a further consensus translation initiator (1993/1994 catalog, page 210). These consensus sequences are suitable for use with the nucleotide sequences of this invention. The sequences are incorporated into constructions comprising the nucleotide sequences, up to and including the ATG (whilst leaving the

second amino acid unmodified), or alternatively up to and including the GTC subsequent to the ATG (with the possibility of modifying the second amino acid of the transgene).

Expression of the nucleotide sequences in transgenic plants is driven by promoters shown to be functional in plants. The choice of promoter will vary depending on the temporal and spatial requirements for expression, and also depending on the target species. Thus, expression of the nucleotide sequences of this invention in leaves, in ears, in inflorescences (*e.g.* spikes, panicles, cobs, *etc.*), in roots, and/or seedlings is preferred. In many cases, however, protection against more than one type of insect pest is sought, and thus expression in multiple tissues is desirable. Although many promoters from dicotyledons have been shown to be operational in monocotyledons and *vice versa*, ideally dicotyledonous promoters are selected for expression in dicotyledons, and monocotyledonous promoters for expression in monocotyledons. However, there is no restriction to the provenance of selected promoters; it is sufficient that they are operational in driving the expression of the nucleotide sequences in the desired cell.

Preferred promoters that are expressed constitutively include promoters from genes encoding actin or ubiquitin and the CaMV 35S and 19S promoters. The nucleotide sequences of this invention can also be expressed under the regulation of promoters that are chemically regulated. This enables the insecticidal toxins to be synthesized only when the crop plants are treated with the inducing chemicals. Preferred technology for chemical induction of gene expression is detailed in the published application EP 0 332 104 (to Ciba-Geigy) and US patent 5,614,395. A preferred promoter for chemical induction is the tobacco PR-1a promoter.

A preferred category of promoters is that which is wound inducible. Numerous promoters have been described which are expressed at wound sites and also at the sites of phytopathogen infection. Ideally, such a promoter should only be active locally at the sites of infection, and in this way the insecticidal toxins only accumulate in cells which need to synthesize the insecticidal toxins to kill the invading insect pest. Preferred promoters of this kind include those described by Stanford *et al.* Mol. Gen. Genet. 215: 200-208 (1989), Xu *et al.* Plant Molec. Biol. 22: 573-588 (1993), Logemann *et al.* Plant Cell 1: 151-158 (1989), Rohrmeier & Lehle, Plant Molec. Biol. 22: 783-792 (1993), Firek *et al.* Plant Molec. Biol. 22: 129-142 (1993), and Warner *et al.* Plant J. 3: 191-201 (1993).

Preferred tissue specific expression patterns include green tissue specific, root specific, stem specific, and flower specific. Promoters suitable for expression in green

tissue include many which regulate genes involved in photosynthesis and many of these have been cloned from both monocotyledons and dicotyledons. A preferred promoter is the maize PEPC promoter from the phosphoenol carboxylase gene (Hudspeth & Grula, Plant Molec. Biol. 12: 579-589 (1989)). A preferred promoter for root specific expression is that described by de Framond (FEBS 290: 103-106 (1991); EP 0 452 269 to Ciba-Geigy). A preferred stem specific promoter is that described in US patent 5,625,136 (to Ciba-Geigy) and which drives expression of the maize *trpA* gene.

Especially preferred embodiments of the invention are transgenic plants expressing at least one of the nucleotide sequences of the invention in a root-preferred or root-specific fashion. Further preferred embodiments are transgenic plants expressing the nucleotide sequences in a wound-inducible or pathogen infection-inducible manner.

In addition to the selection of a suitable promoter, constructions for expression of an insecticidal toxin in plants require an appropriate transcription terminator to be attached downstream of the heterologous nucleotide sequence. Several such terminators are available and known in the art (e.g. *tm1* from CaMV, E9 from *rbcS*). Any available terminator known to function in plants can be used in the context of this invention.

Numerous other sequences can be incorporated into expression cassettes described in this invention. These include sequences which have been shown to enhance expression such as intron sequences (e.g. from *Adh1* and *bronze1*) and viral leader sequences (e.g. from TMV, MCMV and AMV).

It may be preferable to target expression of the nucleotide sequences of the present invention to different cellular localizations in the plant. In some cases, localization in the cytosol may be desirable, whereas in other cases, localization in some subcellular organelle may be preferred. Subcellular localization of transgene encoded enzymes is undertaken using techniques well known in the art. Typically, the DNA encoding the target peptide from a known organelle-targeted gene product is manipulated and fused upstream of the nucleotide sequence. Many such target sequences are known for the chloroplast and their functioning in heterologous constructions has been shown. The expression of the nucleotide sequences of the present invention is also targeted to the endoplasmic reticulum or to the vacuoles of the host cells. Techniques to achieve this are well-known in the art.

Vectors suitable for plant transformation are described elsewhere in this specification. For *Agrobacterium*-mediated transformation, binary vectors or vectors carrying at least one T-DNA border sequence are suitable, whereas for direct gene transfer any vector is suitable and linear DNA containing only the construction of interest may be

preferred. In the case of direct gene transfer, transformation with a single DNA species or co-transformation can be used (Schocher *et al.* *Biotechnology* 4: 1093-1096 (1986)). For both direct gene transfer and *Agrobacterium*-mediated transfer, transformation is usually (but not necessarily) undertaken with a selectable marker which may provide resistance to an antibiotic (kanamycin, hygromycin or methotrexate) or a herbicide (basta). Examples of such markers are neomycin phosphotransferase, hygromycin phosphotransferase, dihydrofolate reductase, phosphinothricin acetyltransferase, 2, 2-dichloropropionic acid dehalogenase, acetohydroxyacid synthase, 5-enolpyruvyl-shikimate-phosphate synthase, haloarylnitrilase, protoporphyrinogen oxidase, acetyl-coenzyme A carboxylase, dihydropteroate synthase, chloramphenicol acetyl transferase, and β -glucuronidase. The choice of selectable or screenable marker for plant transformation is not, however, critical to the invention.

The recombinant DNA described above can be introduced into the plant cell in a number of art-recognized ways. Those skilled in the art will appreciate that the choice of method might depend on the type of plant targeted for transformation. Suitable methods of transforming plant cells include microinjection (Crossway *et al.*, *BioTechniques* 4:320-334 (1986)), electroporation (Riggs *et al.*, *Proc. Natl. Acad. Sci. USA* 83:5602-5606 (1986), *Agrobacterium*-mediated transformation (Hinchey *et al.*, *Biotechnology* 6:915-921 (1988); *See also*, Ishida *et al.*, *Nature Biotechnology* 14:745-750 (June 1996) for maize transformation), direct gene transfer (Paszkowski *et al.*, *EMBO J.* 3:2717-2722 (1984); Hayashimoto *et al.*, *Plant Physiol.* 93:857-863 (1990)(rice)), and ballistic particle acceleration using devices available from Agracetus, Inc., Madison, Wisconsin and Dupont, Inc., Wilmington, Delaware (see, for example, Sanford *et al.*, U.S. Patent 4,945,050; and McCabe *et al.*, *Biotechnology* 6:923-926 (1988)). *See also*, Weissinger *et al.*, *Annual Rev. Genet.* 22:421-477 (1988); Sanford *et al.*, *Particulate Science and Technology* 5:27-37 91987)(onion); Svab *et al.*, *Proc. Natl. Acad. Sci. USA* 87: 8526-8530 (1990) (tobacco chloroplast); Christou *et al.*, *Plant Physiol.* 87:671-674 (1988)(soybean); McCabe *et al.*, *Bio/Technology* 6:923-926 (1988)(soybean); Klein *et al.*, *Proc. Natl. Acad. Sci. USA*, 85:4305-4309 (1988)(maize); Klein *et al.*, *Bio/Technology* 6:559-563 (1988) (maize); Klein *et al.*, *Plant Physiol.* 91:440-444 (1988) (maize); Fromm *et al.*, *Bio/Technology* 8:833-839 (1990); and Gordon-Kamm *et al.*, *Plant Cell* 2: 603-618 (1990) (maize); Koziel *et al.*, *Biotechnology* 11: 194-200 (1993) (maize); Shimamoto *et al.*, *Nature* 338: 274-277 (1989) (rice); Christou *et al.*, *Biotechnology* 9: 957-962 (1991) (rice); Datta *et al.*, *Bio/Technology*

8:736-740 (1990) (rice); European Patent Application EP 0 332 581 (orchardgrass and other *Pooideae*); Vasil *et al.*, *Biotechnology* 11: 1553-1558 (1993) (wheat); Weeks *et al.*, *Plant Physiol.* 102: 1077-1084 (1993) (wheat); Wan *et al.*, *Plant Physiol.* 104: 37-48 (1994) (barley); Jahne *et al.*, *Theor. Appl. Genet.* 89:525-533 (1994)(barley); Umbeck *et al.*, *Bio/Technology* 5: 263-266 (1987) (cotton); Casas *et al.*, *Proc. Natl. Acad. Sci. USA* 90:11212-11216 (Dec. 1993) (sorghum); Somers *et al.*, *Bio/Technology* 10:1589-1594 (Dec. 1992) (oat); Torbert *et al.*, *Plant Cell Reports* 14:635-640 (1995) (oat); Weeks *et al.*, *Plant Physiol.* 102:1077-1084 (1993) (wheat); Chang *et al.*, WO 94/13822 (wheat) and Nehra *et al.*, *The Plant Journal* 5:285-297 (1994) (wheat). A particularly preferred set of embodiments for the introduction of recombinant DNA molecules into maize by microprojectile bombardment can be found in Koziel *et al.*, *Biotechnology* 11: 194-200 (1993), Hill *et al.*, *Euphytica* 85:119-123 (1995) and Koziel *et al.*, *Annals of the New York Academy of Sciences* 792:164-171 (1996). An additional preferred embodiment is the protoplast transformation method for maize as disclosed in EP 0 292 435. Transformation of plants can be undertaken with a single DNA species or multiple DNA species (*i.e.* co-transformation) and both these techniques are suitable for use with the peroxidase coding sequence.

In another preferred embodiment, a nucleotide sequence of the present invention is directly transformed into the plastid genome. A major advantage of plastid transformation is that plastids are generally capable of expressing bacterial genes without substantial modification, and plastids are capable of expressing multiple open reading frames under control of a single promoter. Plastid transformation technology is extensively described in U.S. Patent Nos. 5,451,513, 5,545,817, and 5,545,818, in PCT application no. WO 95/16783, and in McBride *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91, 7301-7305. The basic technique for chloroplast transformation involves introducing regions of cloned plastid DNA flanking a selectable marker together with the gene of interest into a suitable target tissue, *e.g.*, using biolistics or protoplast transformation (*e.g.*, calcium chloride or PEG mediated transformation). The 1 to 1.5 kb flanking regions, termed targeting sequences, facilitate homologous recombination with the plastid genome and thus allow the replacement or modification of specific regions of the plastome. Initially, point mutations in the chloroplast 16S rRNA and rps12 genes conferring resistance to spectinomycin and/or streptomycin are utilized as selectable markers for transformation (Svab, Z., Hajdukiewicz, P., and Maliga, P. (1990) *Proc. Natl. Acad. Sci. USA* 87, 8526-8530; Staub, J. M., and Maliga, P. (1992) *Plant*

Cell 4, 39-45). This resulted in stable homoplasmic transformants at a frequency of approximately one per 100 bombardments of target leaves. The presence of cloning sites between these markers allowed creation of a plastid targeting vector for introduction of foreign genes (Staub, J.M., and Maliga, P. (1993) *EMBO J.* 12, 601-606). Substantial increases in transformation frequency are obtained by replacement of the recessive rRNA or r-protein antibiotic resistance genes with a dominant selectable marker, the bacterial *aadA* gene encoding the spectinomycin-detoxifying enzyme aminoglycoside-3'-adenyltransferase (Svab, Z., and Maliga, P. (1993) *Proc. Natl. Acad. Sci. USA* 90, 913-917). Previously, this marker had been used successfully for high-frequency transformation of the plastid genome of the green alga *Chlamydomonas reinhardtii* (Goldschmidt-Clermont, M. (1991) *Nucl. Acids Res.* 19: 4083-4089). Other selectable markers useful for plastid transformation are known in the art and encompassed within the scope of the invention. Typically, approximately 15-20 cell division cycles following transformation are required to reach a homoplastic state. Plastid expression, in which genes are inserted by homologous recombination into all of the several thousand copies of the circular plastid genome present in each plant cell, takes advantage of the enormous copy number advantage over nuclear-expressed genes to permit expression levels that can readily exceed 10% of the total soluble plant protein. In a preferred embodiment, a nucleotide sequence of the present invention is inserted into a plastid targeting vector and transformed into the plastid genome of a desired plant host. Plants homoplasmic for plastid genomes containing a nucleotide sequence of the present invention are obtained, and are preferentially capable of high expression of the nucleotide sequence.

Formulation of Insecticidal Compositions

The invention also includes compositions comprising at least one of the insecticidal toxins of the present invention. In order to effectively control insect pests such compositions preferably contain sufficient amounts of toxin. Such amounts vary depending on the crop to be protected, on the particular pest to be targeted, and on the environmental conditions, such as humidity, temperature or type of soil. In a preferred embodiment, compositions comprising the insecticidal toxins comprise host cells expressing the toxins without additional purification. In another preferred embodiment, the cells expressing the insecticidal toxins are lyophilized prior to their use as an insecticidal agent. In another embodiment, the insecticidal toxins are engineered to be secreted from the host cells. In

cases where purification of the toxins from the host cells in which they are expressed is desired, various degrees of purification of the insecticidal toxins are reached.

The present invention further embraces the preparation of compositions comprising at least one insecticidal toxin of the present invention, which is homogeneously mixed with one or more compounds or groups of compounds described herein. The present invention also relates to methods of treating plants, which comprise application of the insecticidal toxins or compositions containing the insecticidal toxins, to plants. The insecticidal toxins can be applied to the crop area in the form of compositions or plant to be treated, simultaneously or in succession, with further compounds. These compounds can be both fertilizers or micronutrient donors or other preparations that influence plant growth. They can also be selective herbicides, insecticides, fungicides, bactericides, nematocides, molluscicides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application-promoting adjuvants customarily employed in the art of formulation. Suitable carriers and adjuvants can be solid or liquid and correspond to the substances ordinarily employed in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders or fertilizers.

A preferred method of applying insecticidal toxins of the present invention is by spraying to the environment hosting the insect pest like the soil, water, or foliage of plants. The number of applications and the rate of application depend on the type and intensity of infestation by the insect pest. The insecticidal toxins can also penetrate the plant through the roots via the soil (systemic action) by impregnating the locus of the plant with a liquid composition, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). The insecticidal toxins may also be applied to seeds (coating) by impregnating the seeds either with a liquid formulation containing insecticidal toxins, or coating them with a solid formulation. In special cases, further types of application are also possible, for example, selective treatment of the plant stems or buds. The insecticidal toxins can also be provided as bait located above or below the ground.

The insecticidal toxins are used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation, and are therefore formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations, for example, in polymer substances. Like the nature of the compositions, the methods of application, such as spraying, atomizing, dusting, scattering or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances.

The formulations, compositions or preparations containing the insecticidal toxins and, where appropriate, a solid or liquid adjuvant, are prepared in known manner, for example by homogeneously mixing and/or grinding the insecticidal toxins with extenders, for example solvents, solid carriers and, where appropriate, surface-active compounds (surfactants).

Suitable solvents include aromatic hydrocarbons, preferably the fractions having 8 to 12 carbon atoms, for example, xylene mixtures or substituted naphthalenes, phthalates such as dibutyl phthalate or dioctyl phthalate, aliphatic hydrocarbons such as cyclohexane or paraffins, alcohols and glycols and their ethers and esters, such as ethanol, ethylene glycol monomethyl or monoethyl ether, ketones such as cyclohexanone, strongly polar solvents such as N-methyl-2-pyrrolidone, dimethyl sulfoxide or dimethyl formamide, as well as epoxidized vegetable oils such as epoxidized coconut oil or soybean oil or water.

The solid carriers used e.g. for dusts and dispersible powders, are normally natural mineral fillers such as calcite, talcum, kaolin, montmorillonite or attapulgite. In order to improve the physical properties it is also possible to add highly dispersed silicic acid or highly dispersed absorbent polymers. Suitable granulated adsorptive carriers are porous types, for example pumice, broken brick, sepiolite or bentonite; and suitable nonsorbent carriers are materials such as calcite or sand. In addition, a great number of pregranulated materials of inorganic or organic nature can be used, e.g. especially dolomite or pulverized plant residues.

Suitable surface-active compounds are nonionic, cationic and/or anionic surfactants having good emulsifying, dispersing and wetting properties. The term "surfactants" will also be understood as comprising mixtures of surfactants. Suitable anionic surfactants can be both water-soluble soaps and water-soluble synthetic surface-active compounds.

Suitable soaps are the alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts of higher fatty acids (chains of 10 to 22 carbon atoms), for example the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures which can be obtained for example from coconut oil or tallow oil. The fatty acid methyltaurin salts may also be used.

More frequently, however, so-called synthetic surfactants are used, especially fatty sulfonates, fatty sulfates, sulfonated benzimidazole derivatives or alkylarylsulfonates.

The fatty sulfonates or sulfates are usually in the form of alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts and have a 8 to 22 carbon alkyl radical which also includes the alkyl moiety of alkyl radicals, for example, the sodium

or calcium salt of lignonsulfonic acid, of dodecylsulfate or of a mixture of fatty alcohol sulfates obtained from natural fatty acids. These compounds also comprise the salts of sulfuric acid esters and sulfonic acids of fatty alcohol/ethylene oxide adducts. The sulfonated benzimidazole derivatives preferably contain 2 sulfonic acid groups and one fatty acid radical containing 8 to 22 carbon atoms. Examples of alkylarylsulfonates are the sodium, calcium or triethanolamine salts of dodecylbenzenesulfonic acid, dibutyl-naphthalenesulfonic acid, or of a naphthalenesulfonic acid/formaldehyde condensation product. Also suitable are corresponding phosphates, e.g. salts of the phosphoric acid ester of an adduct of p-nonylphenol with 4 to 14 moles of ethylene oxide.

Non-ionic surfactants are preferably polyglycol ether derivatives of aliphatic or cycloaliphatic alcohols, or saturated or unsaturated fatty acids and alkylphenols, said derivatives containing 3 to 30 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenols.

Further suitable non-ionic surfactants are the water-soluble adducts of polyethylene oxide with polypropylene glycol, ethylenediamine propylene glycol and alkylpolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethylene glycol ether groups and 10 to 100 propylene glycol ether groups. These compounds usually contain 1 to 5 ethylene glycol units per propylene glycol unit.

Representative examples of non-ionic surfactants are nonylphenolpolyethoxyethanols, castor oil polyglycol ethers, polypropylene/polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethylene glycol and octylphenoxyethoxyethanol. Fatty acid esters of polyoxyethylene sorbitan and polyoxyethylene sorbitan trioleate are also suitable non-ionic surfactants.

Cationic surfactants are preferably quaternary ammonium salts which have, as N-substituent, at least one C8-C22 alkyl radical and, as further substituents, lower unsubstituted or halogenated alkyl, benzyl or lower hydroxyalkyl radicals. The salts are preferably in the form of halides, methylsulfates or ethylsulfates, e.g. stearyltrimethylammonium chloride or benzyldi(2-chloroethyl)ethylammonium bromide.

The surfactants customarily employed in the art of formulation are described, for example, in "McCutcheon's Detergents and Emulsifiers Annual," MC Publishing Corp. Ringwood, New Jersey, 1979, and Sisely and Wood, "Encyclopedia of Surface Active Agents," Chemical Publishing Co., Inc. New York, 1980.

EXAMPLES

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Ausubel (ed.), Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (1994); T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor laboratory, Cold Spring Harbor, NY (1989); and by T.J. Silhavy, M.L. Berman, and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984).

A. Isolation Of Nucleotide Sequences Whose Expression Results In Toxins Active Against Lepidopteran Insects

Example 1: Growth of *Xenorhabdus* and *Photorhabdus* Strains

For insect bioassays, the following strains are grown in nutrient broth at 25°C for 3 days in the growth media recommended by ATCC. For DNA isolation, the cultures are grown for 24 hr under the same conditions.

Xenorhabdus nematophilus strain ATCC 19061

Xenorhabdus nematophilus strain Ps1, a USDA isolate

Xenorhabdus poinarii strain ATCC 49122

Photorhabdus luminescens strain Ps5, a USDA isolate

Example 2: Insect Bioassay

Plutella xylostella (Px) bioassays are performed by aliquoting 50µl of each *E.coli* culture on the solid artificial *P. xylostella* diet (Biever and Boldt, Annals of Entomological Society of America, 1971; Shelton, et al J. Ent. Sci 26:17). 4 ml of the diet is poured into 1 oz. clear plastic cups (Bioserve product #9051). 5 neonate *P. xylostella* from a diet adapted lab colony are placed in each diet containing cup and then covered with a white

paper lid (Bioserve product #9049). 10 larvae are assayed per concentration. Trays of cups are placed in an incubator for 3 days at 72°F with a 14:10 (hours) light: dark cycle. The number of live larvae in each cup is recorded.

Example 3: Results of Bioassays

The broth of *Xenorhabdus nematophilus* strain ATCC 19061 gives 100% mortality against *Plutella xylostella* (Px) in the insect bioassay of Example 2. Broth of each of *Xenorhabdus nematophilus* strain Ps1, *Xenorhabdus poinarii* strain ATCC 49122, and *Photorhabdus luminescens* strain Ps5, likewise gives 100% mortality against *Plutella xylostella* (Px) in the insect bioassay of Example 2.

Example 4: Construction of Cosmid Libraries

Total DNA is isolated from *Xenorhabdus nematophilus* strain ATCC 19061 by treating freshly grown cells resuspended in 100 mM Tris pH 8, 10 mM EDTA with 2 mg/ml lysozyme for 30 minutes at 37°C. Proteinase K is added to a final concentration of 100 µg/ml in 0.5% SDS and incubated at 45°C. The solution clears and becomes very viscous. The SDS concentration is increased to 1% and 300 mM NaCl and equal volume of phenol-chloroform-isoamyl alcohol are added. The sample is gently mixed for 5 minutes and centrifuged at 3K. This is repeated twice. The aqueous phase is then mixed with 0.7 volumes isopropanol and centrifuged. The DNA pellet is washed three times with 70% ethanol and gently resuspended in 0.5X TE. 6 µg of DNA are treated with 0.3 unit of *Sau3A* per µg of DNA at 37°C for 3.5 minutes in a volume of 100 µl. The sample is then heated for 30 minutes at 65°C to inactivate the enzyme, then incubated with 2 units of calf intestinal alkaline phosphatase for 30 minutes at 37°C. The sample is mixed with an equal volume of phenol-chloroform-isoamyl alcohol and centrifuged. The aqueous phase is removed and mixed with 0.7 volumes isopropanol and centrifuged. The pellet is resuspended in 0.5X TE at a concentration of 100 ng/ml.

SuperCos cosmid vector (Stratagene, La Jolla, CA) is prepared as described by the supplier utilizing the *BamHI* cloning site. Prepared SuperCos at 100 ng/ml is ligated with the *X. nematophilus* DNA previously digested with *Sau3A* at a ratio of 2:1 in a 5 µl volume

overnight at 6°C. The ligation mixture is packaged using Gigapack XL III (Stratagene) as described by the supplier. Packaged phages are infected into XL-1MR *E. coli* cells (Stratagene) as described by the supplier. The cosmid library is plated on L-agar with 50 µg/ml kanamycin and incubated 16 hours at 37°C. 500 colonies are patched to fresh L-kan plates at a density of 50/plate. The cells are washed off with L broth and mixed with 20% glycerol and frozen at -80°C.

In the case of the 4.2 Mb large genome of *X. nematophilus*, 450 clones with an average size of 40 Kb correspond to a 4-fold coverage of the genome. Therefore, screening of 450 clones should result in a 99% probability of finding any gene.

Cosmid libraries from *Xenorhabdus nematophilus* strain Ps1, *Xenorhabdus poinarii* strain ATCC 49122, and *Photorhabdus luminescens* strain Ps5 are constructed in a like manner.

Example 5: Results of the Cosmids Bioassays and Identification of Clones Having Insecticidal Activity

400 *E. coli* clones from each cosmid library are screened by insect bioassay yielding clones with activity against *Plutella xylostella*. An insecticidal cosmid clone from *Xenorhabdus nematophilus* strain ATCC 19061 is identified as pCIB9362. A 42 kb insecticidal cosmid clone from *Xenorhabdus nematophilus* strain Ps1 is identified as pCIB9379. A 42 kb insecticidal cosmid clone from *Xenorhabdus poinarii* strain ATCC 49122 is identified as pCIB9354. A 7 kb insecticidal cosmid clone from *Photorhabdus luminescens* strain Ps5 is identified as pCIB9383-21.

Example 6: Isolation of Subclones Having Insecticidal Activity

Clone pCIB9362 is digested with *SacII* and a 9 kb DNA fragment is isolated. This fragment is ligated into Bluescript cut with *SacII*. The ligation mixture is transformed into DH5α *E. coli* cells as described in Molecular Cloning, second edition (Sambrook et al.). The transformation mixture is plated on L agar plus 100 µg/ml ampicillin and incubated at 37°C overnight. Isolated colonies are grown up in L broth with 100 µg/ml ampicillin and plasmid DNA isolated by alkaline minipreps as described in Molecular Cloning, second edition. The 9 kb *SacII* clone is identified as pCIB9362-3 and gives 100% mortality when bioassayed

against *Plutella xylostella*. 3 µg of pCIB9362-3 is isolated, digested with 0.3 unit of *Sau3A* per µg DNA for 4 , 6 and 8 min. at 37°C and heated at 75°C for 15 min. Samples are pooled and ligated into pUC19 previously digested with *BamHI* and treated with calf intestinal alkaline phosphatase. The ligation is transformed into DH5α *E. coli* cells, plated on L agar with Xgal/Amp as described in Molecular Cloning and grown overnight at 37°C. White colonies are picked and grown up in L broth with 100 µg/ml ampicillin and plasmid DNA is isolated as previously described. DNA is digested with *EcoRI/HindIII* and novel restriction patterns are sequenced. Sequencing primers are ordered from Genosys Biotechnologies (Woodlands, Tx). Sequencing is performed using the dideoxy chain-termination method and is completed using Applied Biosystems Inc. model 377 automated DNA sequencer (Foster City, CA). The sequence is assembled using Sequencher 3.0 from Gene Codes Corporation (Ann Arbor, Michigan).

After identification of restriction sites and of potential ORF's, pCIB9362-3 is digested with *ClaI* and a 3.0 kb fragment is isolated cloned into Bluescript and transformed into DH5α *E. coli* cells. The isolated colonies are grown as previously described and plasmid DNA isolated by the alkaline method. The subclone is identified as pCIB9369 and gives 100% mortality against *Plutella xylostella* in a bioassay. pCIB9369 has been deposited on November 12, 1997 and identified by NRRL Number B-21883 at the USDA ARS Patent Culture Collection.

A 20 kb fragment identified as pCIB9381 is subcloned from cosmid pCIB9379 using a *NotI* digest.

Example 7: Bioassay Results

Insect Bioassays are conducted for pCIB9369 for a variety of insects.

Insect	pCIB9369
<i>Plutella xylostella</i>	+++
<i>Heliothis virescens</i>	na
<i>Helioverpa zea</i>	na
<i>Spodoptera exguia</i>	na
<i>C. elegans</i>	na

- 30 -

na = not active
+ = significant growth inhibition
++ = >40% mortality, but less than 100%
+++ = 100% mortality

These results show that the insecticidal toxin resulting from expression of the 3.0 kb nucleotide sequence in pCIB9369 is highly active against *Plutella xylostella*.

Bioassays for pCIB9381, pCIB9354, and pCIB9383-21 also show high insecticidal activity against *Plutella xylostella*.

Example 8: Size Fraction of the Insecticidal Activity

Xenorhabdus nematophilus cosmid clone pCIB9369 and Stratagene's Blue Script vector in *E. coli* host DH5 are grown in media consisting of 50% Terrific broth and 50% Luria broth, supplemented with 50 µg/ml of ampicillin. Shake flask cultures (300 ml in 1000 ml baffled flasks) are grown at 250 RPM, overnight at 37°C. Cultures of each strain are centrifuged at 7,000 RPM in a Sorvall GS-3 rotor at 4°C. The pelleted cells are resuspended in 30 ml of 50mM NaCl, 25 mM Tris base, pH 7.0. The concentrated cells are disrupted by sonication using a Branson Model 450 Sonicator for approximately eight 10 second cycles with cooling on ice between cycles. The sonicates are centrifuged in a Sorvall SS34 rotor at 6,000 RPM for 10 minutes at 4°C. The resultant supernatants are filtered through a 0.2 µ filter. The pellets from the centrifuged sonicates are resuspended in 30 ml of 50mM NaCl, 25 mM Tris base, pH 7.0.

The 3 ml fractions of the filtrates are applied to Bio-Rad Econo-Pac 10DG columns that had been previously equilibrated with 10 ml of 50mM NaCl, 25 mM Tris base, pH 7.0. The flow through collected during sample loading is discarded. The samples are fractionated with two subsequent additions of 4 ml each of the NaCl - Tris equilibration buffer. The first three fractions are saved for testing. The first fraction should contain all material above about 6,000 mol. wt. The subsequent fractions should contain material smaller than 6,000 mol. wt.

A sample of the sonicated filtrate and the resuspended pellet following sonication, are tested along with the three fractions from the 10DG column for activity on *P. xylostella* neonates in surface contamination assays. The filtered supernatant of the sonicate and the first column fraction from the 9369 sample is highly active on *P. xylostella*. The second and third fractions from the 9369 sample are not active. None of the samples from the DH5a

with the Blue Script plasmid culture have activity. These results suggest that the insecticidal activity encoded on *X. nematophilus* clone pCIB9369 as well as the homologues from pCIB9381, pCIB9354, and pCIB9383-21 are larger than 6,000 molecular weight.

Example 9: Stability of the Insecticidal Activity

A 300 ml of Luria broth supplemented with 100 µg/ml ampicillin is inoculated with pCIB9369 and grown over night at 37°C. The samples are placed in sterile 15 ml screw cap tubes and stored at 22°C and 4°C. One sample is centrifuged and the supernatant removed, freeze dried and stored at 22°C. These samples are stored in these conditions for 2 weeks and then bioassayed against Px. The freeze dried material is resuspended in the same volume as prior to freeze drying the sample. All samples are resuspended by vortexing. Another sample is treated at 100°C for 5 minutes.

<u>Treatment</u>	<u>Result</u>
22°C (2 weeks)	++
4°C (2 weeks)	++
Freeze Dried (2 weeks)	++
100°C for 5 minutes	na

na = not active.

Example 10: Heat Inactivation of the Insecticidal Activity

The heat stability of the toxin is determined. Overnight cultures of the *E. coli* strain pCIB9369 (*E. coli* host DH5a, carrying the 3.0 kb DNA of *Xenorhabdus nematophilus*) are grown in a 50:50 mixture of Luria broth and terrific broth. Cultures are grown at 37°C in culture tubes on a tube roller. Samples of one ml each of the culture are placed in a 1.5 ml eppendorf tube and placed at 60°C, 80°C. The samples are removed after five minutes and allowed to cool to room temperature. This sample along with an untreated portion of the culture is assayed on *P. xylostella*. 50µl of sample of sample is spread on diet, allowed to dry and neonate larvae *P. xylostella* applied to the surface. The assay is incubated for 5 days at room temperature.

The untreated sample and the sample treated at 60°C cause 100% mortality. The sample treated at 80°C and a diet alone control do not cause observable mortality.

Example 11: Protease Treatment of the Insecticidal Activity

Xenorhabdus nematophilus cosmid clone pCIB9369 and Stratagene's Blue Script vector in *E. coli* host DH5 are grown in media consisting of 50% Terrific broth and 50% Luria broth, supplemented with 50 µg/ml of ampicilin. Shake flask cultures (300 ml in 1000 ml baffled flasks) are grown at 250 RPM, overnight at 37°C. Cultures of each strain are centrifuged at 7,000 RPM in a Sorvall GS-3 rotor at 4°C. The pelleted cells are resuspended in 30 ml of 50mM NaCl, 25 mM Tris base, pH 7.0. The concentrated cells are disrupted by sonication using a Branson Model 450 Sonicator for approximately eight 10 second cycles with cooling on ice between cycles. The sonicates are centrifuged in a Sorvall SS34 rotor at 6,000 RPM for 10 minutes at 4°C. The resultant supernatants are filtered through a 0.2 µ filter. One ml samples of the supernatants are adjusted to 5mM Ca++ with the addition of CaCl₂. Protease K (Gibco BRL; Gaithersburg, MD) is added to 500 µg / ml. Samples are incubated for 2 and 24 hr at 37°C. Control samples are prepared and incubated with added Ca++ but no protease.

The sonicate filtrate from pCIB9369 and the pCIB9369 samples incubated in the presence of 5mM Ca++ produce 100% mortality on *Plutella xylostella* neonate larvae. The pCIB9369 samples incubated with protease K in addition to Ca++ show slightly less mortality, approximately 90% mortality on *Plutella*.

Example 12: Sequence Comparisons with the Protein Sequence of cry3A and the Protein Sequence of a Juvenile Hormone Esterase

The nucleotide sequence of pCIB9369 (SEQ ID NO:1) reveals two open reading frames (ORFs) at nucleotides 569-976 and 1045-2334. ORF #1 has no homology to any sequences in Genbank after a search with the UWGCG Blast and Gap programs. A Gap analysis of the protein encoded by ORF #2 of pCIB9369 by the Blast program identifies some insignificant homology (21% identity) to *Bacillus thuringensis* cry3A protein. However, a Gap analysis of the protein encoded by ORF #2 of pCIB9369 (SEQ ID NO:3) by the Blast program does identify homology (30.6% AA identity and 44.1% AA similarity) to a juvenile hormone esterase-related protein (GenBank accession 2921553; Henikoff et al., *PNAS USA* 89: 10915-10919 (1992)).

The nucleotide sequences of pCIB9381, pCIB9354, and pCIB9383-21 also reveal two open reading frames in each of these clones. The nucleotide sequences of the two ORFs in each of pCIB9381 and pCIB9383-21 are all over 90% identical to those in pCIB9369. Hence, the ORF #2 proteins of pCIB9381 and pCIB9383-21 have essentially the same homology to the juvenile hormone esterase-related protein as does the ORF #2 protein of pCIB9369. The nucleotide sequence of ORF #1 of pCIB9354 is 77% identical to the nucleotide sequence of ORF #1 of pCIB9369, and the nucleotide sequence of ORF #2 of pCIB9354 is 79% identical to the nucleotide sequence of ORF #2 of pCIB9369. The ORF #2 protein of pCIB9354 also has homology to the juvenile hormone esterase-related protein (29.2% AA identity and 42.2% AA similarity).

Example 13: Sequence Comparison of pCIB9369 and Sequences from WO 98/08388

Twenty-two sequences of 60 nucleotides each (60-mers) are derived from the 38.2 kb DNA fragment whose nucleotide sequence is described in WO 98/08388 and are compared to the nucleotide sequence of pCIB9362-3, which comprises pCIB9369. The first 60-mer starts at base 1 in the 38.2 kb DNA fragment, while the other 60-mers are located at approximately 2 kb intervals on the DNA fragment. Their positions on the 38.2 kb DNA fragment are listed below:

1-60; 2,041-2,100; 4,021-4,080; 6,001-6,060; 8,041-8,100; 10,021-10,080; 12,001-12,060; 14,041-14,100; 16,021-16,080; 18,001-18,060; 20,041-20,100; 22,021-22,080; 24,001-24,060; 26,041-26,100; 28,021-28,080; 30,001-30,060; 32,041-32,100; 34,021-34,080; 36,001-36,060; 38,041-38,100; 38,161-38,220.

The sequences are compared using UWGCG Gap program and each of the 22 60-mer sequences as well as their complementary sequences are tested. The results of these alignments indicate that the highest percentage of identity is 53%, which is not considered to be a significant homology in the art.

Example 14: Southern Blot Analysis using Probes Derived from WO 98/08388 Sequences

Pairs of oligonucleotides are designed to amplify DNA fragments of the 38.2 kb DNA fragment published in WO 98/08388. The oligonucleotides are ordered from Genosys Biotechnologies (The Woodlands, Texas) and their positions in the 38.2 kb DNA fragment are indicated below. Also listed are their and the sizes of the amplified PCR fragments:

VK1046: positions 20-40

VK1047: positions 2,078-2,100

Size of the PCR fragment amplified using VK1046 and VK1047: 2,080 bp

VK1048: positions 11,221-11,241

VK1049: positions 13,360-13,380

Size of the PCR fragment amplified using VK1048 and VK1049: 2,120 bp

VK1050: positions 26,581-26,601

VK1051: positions 28,537-28,560

Size of the PCR fragment amplified using VK1050 and VK1051: 1,979 bp

VK1052: positions 18,901-18,921

VK1053: positions 20,321-20,340

Size of the PCR fragment amplified using VK1052 and VK1053: 1,439 bp

VK1054: positions 34,261-34,281

VK1055: positions 35,320-35,340 BP

Size of the PCR fragment amplified using VK1054 and VK1055: 1,079 bp

The PCR reactions are completed using a Perkin-Elmer 9600 Thermo-Cycler with the following conditions: 94°C, 2 min.; then 30 cycles at 94°C, 30 sec; 54°C, 30 sec; 72°C, 4 min. The samples contain 800 ng of *Xenorhabdus nematophilus* DNA, 0.1-0.5 µM of each pair of oligonucleotides, 250 µM dNTP, 5U Taq Polymerase and 1X buffer (Perkin-Elmer) in a final volume of 100 µl. The completed reactions are precipitated in ethanol, resuspended in TE and loaded on a 1% SeaPlaque (FMC, Rockland, Maine) TBE gel. After electrophoresis, the fragments are cut out from the gel after ethidium bromide staining and visualization under UV light. The gel slices are melted at 65°C and 10 µl aliquots are mixed with 10 µl distilled water, boiled for 5 min. and placed on ice. Then, 15 µl of Random Priming label buffer (GIBCO-BRL, Gaithersburg, MD), 6 µl dNTP mix (without dCTP), 80 µCi α-dCT³²P and 1 µl Klenow are mixed. The labeling reaction is carried out during 60 min. at room temperature. The samples are cleaned up on Nick columns (Pharmacia Biotech)

according to the supplier's recommendations. The probes are boiled for 5 min. and placed on ice.

A Southern blot is performed by digesting *Xenorhabdus nematophilus* total DNA, DNA derived from cosmids pCIB9362 and pCIB9363 (these cosmids overlap over 25 kb and both contain the DNA fragment of pCIB9369; pCIB9362 was used for subcloning), DNA derived from subclones pCIB9362-3 (9 kb *SacII* fragment) and pCIB9369 (2.96 kb *Clal* fragment), digested with *Clal*, *SacII* or *HindIII*. The digestion reactions are loaded on a 0.75% agarose TBE gel and run overnight. A picture is taken and the gel is treated as described by Bio-Rad for blotting to a Zeta-Probe hybridization membrane. After blotting, the membrane is baked at 80°C for 30 min. The membrane is then placed in 7% SDS, 250 mM sodium phosphate, pH 7.2 and incubated at 67°C for 30 min. Fresh solution is added and after equilibration to 67°C, the radioactive probes described above are added and allowed to hybridize overnight. The membrane is washed in 2X SSC, 0.5% SDS for 30 min. at 67°C and then 0.5X SSC, 0.5% SDS for 30 min. at 67°C. The membrane is exposed on to a film for 1 hr and 3 hr. The film is developed and the results show that the PCR probes from the WO 98/08388 sequence do not hybridize to the DNA of the cosmids or the DNA of the subclones described in this invention. However, a strong hybridization signal is observed with *X. nematophilus* DNA.

These results corroborate the results of the sequence comparisons and show that clone pCIB9369 is different from the nucleotide sequence described in WO 98/08388.

B. Expression of the Nucleic Acid Sequences of the Invention in Heterologous Microbial Hosts

Microorganisms which are suitable for the heterologous expression of the nucleotide sequences of the invention are all microorganisms which are capable of colonizing plants or the rhizosphere. As such they will be brought into contact with insect pests. These include gram-negative microorganisms such as *Pseudomonas*, *Enterobacter* and *Serratia*, the gram-positive microorganism *Bacillus* and the fungi *Trichoderma*, *Gliocladium*, and *Saccharomyces cerevisiae*. Particularly preferred heterologous hosts are *Pseudomonas fluorescens*, *Pseudomonas putida*, *Pseudomonas cepacia*, *Pseudomonas aureofaciens*, *Pseudomonas aurantiaca*, *Enterobacter cloacae*, *Serratia marcescens*, *Bacillus subtilis*,

Bacillus cereus, *Trichoderma viride*, *Trichoderma harzianum*, *Gliocladium virens*, and *Saccharomyces cerevisiae*.

Example 19: Expression of the Nucleotide Sequences in *E. coli* and Other Gram-Negative Bacteria

Many genes have been expressed in gram-negative bacteria in a heterologous manner. Expression vector pKK223-3 (Pharmacia catalogue # 27-4935-01) allows expression in *E. coli*. This vector has a strong *tac* promoter (Brosius, J. *et al.*, *Proc. Natl. Acad. Sci. USA* 81) regulated by the *lac* repressor and induced by IPTG. A number of other expression systems have been developed for use in *E. coli*. The thermoinducible expression vector pP_L (Pharmacia #27-4946-01) uses a tightly regulated bacteriophage λ promoter which allows for high level expression of proteins. The *lac* promoter provides another means of expression but the promoter is not expressed at such high levels as the *tac* promoter. With the addition of broad host range replicons to some of these expression system vectors, expression of the nucleotide sequence in closely related gram negative-bacteria such as *Pseudomonas*, *Enterobacter*, *Serratia* and *Erwinia* is possible. For example, pLRKD211 (Kaiser & Kroos, *Proc. Natl. Acad. Sci. USA* 81: 5816-5820 (1984)) contains the broad host range replicon *ori T* which allows replication in many gram-negative bacteria.

In *E. coli*, induction by IPTG is required for expression of the *tac* (*i.e.* *trp-lac*) promoter. When this same promoter (*e.g.* on wide-host range plasmid pLRKD211) is introduced into *Pseudomonas* it is constitutively active without induction by IPTG. This *trp-lac* promoter can be placed in front of any gene or operon of interest for expression in *Pseudomonas* or any other closely related bacterium for the purposes of the constitutive expression of such a gene. Thus, a nucleotide sequence whose expression results in an insecticidal toxin can therefore be placed behind a strong constitutive promoter, transferred to a bacterium which has plant or rhizosphere colonizing properties turning this organism to an insecticidal agent. Other possible promoters can be used for the constitutive expression of the nucleotide sequence in gram-negative bacteria. These include, for example, the promoter from the *Pseudomonas* regulatory genes *gafA* and *lemA* (WO 94/01561) and the *Pseudomonas savastanoi* IAA operon promoter (Gaffney *et al.*, *J. Bacteriol.* 172: 5593-5601 (1990)).

Example 20: Expression of the Nucleotide Sequences in Gram-Positive Bacteria

Heterologous expression of the nucleotides sequence in gram-positive bacteria is another means of producing the insecticidal toxins. Expression systems for *Bacillus* and *Streptomyces* are the best characterized. The promoter for the erythromycin resistance gene (*ermR*) from *Streptococcus pneumoniae* has been shown to be active in gram-positive aerobes and anaerobes and also in *E.coli* (Trieu-Cuot *et al.*, Nucl Acids Res 18: 3660 (1990)). A further antibiotic resistance promoter from the thiostreptone gene has been used in *Streptomyces* cloning vectors (Bibb, Mol Gen Genet 199: 26-36 (1985)). The shuttle vector pHT3101 is also appropriate for expression in *Bacillus* (Lereclus, FEMS Microbiol Lett 60: 211-218 (1989)). A significant advantage of this approach is that many gram-positive bacteria produce spores which can be used in formulations that produce insecticidal agents with a longer shelf life. *Bacillus* and *Streptomyces* species are aggressive colonizers of soils

Example 21: Expression of the Nucleotide Sequences in Fungi

Trichoderma harzianum and *Gliocladium virens* have been shown to provide varying levels of biocontrol in the field (US 5,165,928 and US 4,996,157, both to Cornell Research Foundation). A nucleotide sequence whose expression results in an insecticidal toxin could be expressed in such a fungus. This could be accomplished by a number of ways which are well known in the art. One is protoplast-mediated transformation of the fungus by PEG or electroporation-mediated techniques. Alternatively, particle bombardment can be used to transform protoplasts or other fungal cells with the ability to develop into regenerated mature structures. The vector pAN7-1, originally developed for *Aspergillus* transformation and now used widely for fungal transformation (Curragh *et al.*, Mycol. Res. 97(3): 313-317 (1992); Tooley *et al.*, Curr. Genet. 21: 55-60 (1992); Punt *et al.*, Gene 56: 117-124 (1987)) is engineered to contain the nucleotide sequence. This plasmid contains the *E. coli* the hygromycin B resistance gene flanked by the *Aspergillus nidulans* *gpd* promoter and the *trpC* terminator (Punt *et al.*, Gene 56: 117-124 (1987)).

In a preferred embodiment, the nucleic acid sequences of the invention are expressed in the yeast *Saccharomyces cerevisiae*. For example, each of the two ORF's

from pCIB9369, pCIB9381, pCIB9354, or pCIB9383 are cloned into individual vectors with the GAL1 inducible promoter and the CYC1 terminator. Each vector has ampicillin resistance and the 2 micron replicon. The vectors preferably differ in their yeast growth markers. The constructs are transformed into *S. cerevisiae* independently and together. The ORFs are expressed together and tested for protein expression and insecticidal activity.

C. Formulation of the Insecticidal Toxin

Insecticidal formulations are made using active ingredients which comprise either the isolated toxin or alternatively suspensions or concentrates of cells which produce it and which are described in the examples above. For example, *E. coli* cells expressing the insecticidal toxin may be used for the control of the insect pests. Formulations are made in liquid or solid form and are described below.

Example 18: Liquid Formulation of Insecticidal Compositions

In the following examples, percentages of composition are given by weight:

<u>1. Emulsifiable concentrates:</u>	<u>a</u>	<u>b</u>	<u>c</u>
Active ingredient	20%	40%	50%
Calcium dodecylbenzenesulfonate	5%	8%	6%
Castor oil polyethylene glycol ether (36 moles of ethylene oxide)	5%	-	-
Tributylphenol polyethylene glyco ether (30 moles of ethylene oxide)	-	12%	4%
Cyclohexanone	-	15%	20%
Xylene mixture	70%	25 %	20%

Emulsions of any required concentration can be produced from such concentrates by dilution with water.

- 39 -

<u>2. Solutions:</u>	<u>a</u>	<u>b</u>	<u>c</u>	<u>d</u>
Active ingredient	80%	10%	5%	95%
Ethylene glycol monomethyl ether	20%	-	-	-
Polyethylene glycol 400	-	70%	-	-
N-methyl-2-pyrrolidone	-	20 %	-	-
Epoxidised coconut oil	-	-	1%	5%
Petroleum distillate	-	-	94%	-
(boiling range 160-190°)				

These solutions are suitable for application in the form of microdrops.

<u>3. Granulates:</u>	<u>a</u>	<u>b</u>
Active ingredient	5%	10%
Kaolin	94%	-
Highly dispersed silicic acid	1%	-
Attapulgit	-	90%

The active ingredient is dissolved in methylene chloride, the solution is sprayed onto the carrier, and the solvent is subsequently evaporated off in vacuo.

<u>4. Dusts:</u>	<u>a</u>	<u>b</u>
Active ingredient	2%	5%
Highly dispersed silicic acid	1%	5%
Talcum	97%	-
Kaolin	-	90%

Ready-to-use dusts are obtained by intimately mixing the carriers with the active ingredient.

Example 19: Solid Formulation of Insecticidal Compositions

In the following examples, percentages of compositions are by weight.

- 40 -

<u>1. Wettable powders:</u>	<u>a</u>	<u>b</u>	<u>c</u>
Active ingredient	20%	60%	75%
Sodium lignosulfonate	5%	5%	-
Sodium lauryl sulfate	3%	-	5%
Sodium diisobutylphenylene sulfonate	-	6%	10 %
Octylphenol polyethylene glycol ether (7-8 moles of ethylene oxide)	-	2%	-
Highly dispersed silicic acid	5%	27%	10%
Kaolin	67%	-	-

The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording wettable powders which can be diluted with water to give suspensions of the desired concentrations.

2. Emulsifiable concentrate:

Active ingredient	10%
Octylphenol polyethylene glycol ether (4-5 moles of ethylene oxide)	3%
Calcium dodecylbenzenesulfonate	3%
Castor oil polyglycol ether (36 moles of ethylene oxide)	4%
Cyclohexanone	30%
Xylene mixture	50%

Emulsions of any required concentration can be obtained from this concentrate by dilution with water.

<u>3. Dusts:</u>	<u>a</u>	<u>b</u>
Active ingredient	5%	8%
Talcum	95%	-
Kaolin	-	92%

Ready-to-use dusts are obtained by mixing the active ingredient with the carriers, and grinding the mixture in a suitable mill.

4. Extruder granulate:

Active ingredient	10%
Sodium lignosulfonate	2%
Carboxymethylcellulose	1%
Kaolin	87%

The active ingredient is mixed and ground with the adjuvants, and the mixture is subsequently moistened with water. The mixture is extruded and then dried in a stream of air.

5. Coated granulate:

Active ingredient	3%
Polyethylene glycol 200	3%
Kaolin	94%

The finely ground active ingredient is uniformly applied, in a mixer, to the kaolin moistened with polyethylene glycol. Non-dusty coated granulates are obtained in this manner.

6. Suspension concentrate:

Active ingredient	40%
Ethylene glycol	10%
Nonylphenol polyethylene glycol (15 moles of ethylene oxide)	6%
Sodium lignosulfonate	10%
Carboxymethylcellulose	1%
37 % aqueous formaldehyde solution	0.2%
Silicone oil in 75 % aqueous emulsion	0.8%
Water	32%

The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired concentration can be obtained by dilution with water.

The insecticidal formulations described above are applied to the plants according to methods well known in the art, in such amounts that the insect pests are controlled by the insecticidal toxin.

D. Expression of the Nucleotide Sequences in Transgenic Plants

The nucleic acid sequences described in this application can be incorporated into plant cells using conventional recombinant DNA technology. Generally, this involves inserting a coding sequence of the invention into an expression system to which the coding sequence is heterologous (i.e., not normally present) using standard cloning procedures known in the art. The vector contains the necessary elements for the transcription and translation of the inserted protein-coding sequences. A large number of vector systems known in the art can be used, such as plasmids, bacteriophage viruses and other modified viruses. Suitable vectors include, but are not limited to, viral vectors such as lambda vector systems λ gt11, λ gt10 and Charon 4; plasmid vectors such as pBI121, pBR322, pACYC177, pACYC184, pAR series, pKK223-3, pUC8, pUC9, pUC18, pUC19, pLG339, pRK290, pKC37, pKC101, pCDNALL; and other similar systems. The components of the expression system may also be modified to increase expression. For example, truncated sequences, nucleotide substitutions or other modifications may be employed. The expression systems described herein can be used to transform virtually any crop plant cell under suitable conditions. Transformed cells can be regenerated into whole plants such that the nucleotide sequence of the invention confer insect resistance to the transgenic plants.

Example 22: Modification of Coding Sequences and Adjacent Sequences

The nucleotide sequences described in this application can be modified for expression in transgenic plant hosts. A host plant expressing the nucleotide sequences and which produces the insecticidal toxins in its cells has enhanced resistance to insect attack and is thus better equipped to withstand crop losses associated with such attack.

The transgenic expression in plants of genes derived from microbial sources may require the modification of those genes to achieve and optimize their expression in plants. In particular, bacterial ORFs which encode separate enzymes but which are encoded by the same transcript in the native microbe are best expressed in plants on separate transcripts.

To achieve this, each microbial ORF is isolated individually and cloned within a cassette which provides a plant promoter sequence at the 5' end of the ORF and a plant transcriptional terminator at the 3' end of the ORF. The isolated ORF sequence preferably includes the initiating ATG codon and the terminating STOP codon but may include additional sequence beyond the initiating ATG and the STOP codon. In addition, the ORF may be truncated, but still retain the required activity; for particularly long ORFs, truncated versions which retain activity may be preferable for expression in transgenic organisms. By "plant promoter" and "plant transcriptional terminator" it is intended to mean promoters and transcriptional terminators which operate within plant cells. This includes promoters and transcription terminators which may be derived from non-plant sources such as viruses (an example is the Cauliflower Mosaic Virus).

In some cases, modification to the ORF coding sequences and adjacent sequence is not required. It is sufficient to isolate a fragment containing the ORF of interest and to insert it downstream of a plant promoter. For example, Gaffney *et al.* (Science 261: 754-756 (1993)) have expressed the *Pseudomonas nahG* gene in transgenic plants under the control of the CaMV 35S promoter and the CaMV *tml* terminator successfully without modification of the coding sequence and with x bp of the *Pseudomonas* gene upstream of the ATG still attached, and y bp downstream of the STOP codon still attached to the *nahG* ORF. Preferably as little adjacent microbial sequence should be left attached upstream of the ATG and downstream of the STOP codon. In practice, such construction may depend on the availability of restriction sites.

In other cases, the expression of genes derived from microbial sources may provide problems in expression. These problems have been well characterized in the art and are particularly common with genes derived from certain sources such as *Bacillus*. These problems may apply to the nucleotide sequence of this invention and the modification of these genes can be undertaken using techniques now well known in the art. The following problems may be encountered:

1. Codon Usage.

The preferred codon usage in plants differs from the preferred codon usage in certain microorganisms. Comparison of the usage of codons within a cloned microbial ORF to usage in plant genes (and in particular genes from the target plant) will enable an identification of the codons within the ORF which should preferably be changed. Typically

plant evolution has tended towards a strong preference of the nucleotides C and G in the third base position of monocotyledons, whereas dicotyledons often use the nucleotides A or T at this position. By modifying a gene to incorporate preferred codon usage for a particular target transgenic species, many of the problems described below for GC/AT content and illegitimate splicing will be overcome.

2. GC/AT Content.

Plant genes typically have a GC content of more than 35%. ORF sequences which are rich in A and T nucleotides can cause several problems in plants. Firstly, motifs of ATTTA are believed to cause destabilization of messages and are found at the 3' end of many short-lived mRNAs. Secondly, the occurrence of polyadenylation signals such as AATAAA at inappropriate positions within the message is believed to cause premature truncation of transcription. In addition, monocotyledons may recognize AT-rich sequences as splice sites (see below).

3. Sequences Adjacent to the Initiating Methionine.

Plants differ from microorganisms in that their messages do not possess a defined ribosome binding site. Rather, it is believed that ribosomes attach to the 5' end of the message and scan for the first available ATG at which to start translation. Nevertheless, it is believed that there is a preference for certain nucleotides adjacent to the ATG and that expression of microbial genes can be enhanced by the inclusion of a eukaryotic consensus translation initiator at the ATG. Clontech (1993/1994 catalog, page 210, incorporated herein by reference) have suggested one sequence as a consensus translation initiator for the expression of the *E. coli uidA* gene in plants. Further, Joshi (NAR 15: 6643-6653 (1987), incorporated herein by reference) has compared many plant sequences adjacent to the ATG and suggests another consensus sequence. In situations where difficulties are encountered in the expression of microbial ORFs in plants, inclusion of one of these sequences at the initiating ATG may improve translation. In such cases the last three nucleotides of the consensus may not be appropriate for inclusion in the modified sequence due to their modification of the second AA residue. Preferred sequences adjacent to the initiating methionine may differ between different plant species. A survey of 14 maize genes located in the GenBank database provided the following results:

Position Before the Initiating ATG in 14 Maize Genes:

	<u>-10</u>	<u>-9</u>	<u>-8</u>	<u>-7</u>	<u>-6</u>	<u>-5</u>	<u>-4</u>	<u>-3</u>	<u>-2</u>	<u>-1</u>
C	3	8	4	6	2	5	6	0	10	7
T	3	0	3	4	3	2	1	1	1	0
A	2	3	1	4	3	2	3	7	2	3
G	6	3	6	0	6	5	4	6	1	5

This analysis can be done for the desired plant species into which the nucleotide sequence is being incorporated, and the sequence adjacent to the ATG modified to incorporate the preferred nucleotides.

4. Removal of Illegitimate Splice Sites.

Genes cloned from non-plant sources and not optimized for expression in plants may also contain motifs which may be recognized in plants as 5' or 3' splice sites, and be cleaved, thus generating truncated or deleted messages. These sites can be removed using the techniques well known in the art.

Techniques for the modification of coding sequences and adjacent sequences are well known in the art. In cases where the initial expression of a microbial ORF is low and it is deemed appropriate to make alterations to the sequence as described above, then the construction of synthetic genes can be accomplished according to methods well known in the art. These are, for example, described in the published patent disclosures EP 0 385 962 (to Monsanto), EP 0 359 472 (to Lubrizol) and WO 93/07278 (to Ciba-Geigy), all of which are incorporated herein by reference. In most cases it is preferable to assay the expression of gene constructions using transient assay protocols (which are well known in the art) prior to their transfer to transgenic plants.

Example 23: Construction of Plant Expression Cassettes

Coding sequences intended for expression in transgenic plants are first assembled in expression cassettes behind a suitable promoter expressible in plants. The expression cassettes may also comprise any further sequences required or selected for the expression of the transgene. Such sequences include, but are not restricted to, transcription terminators, extraneous sequences to enhance expression such as introns, vital sequences, and sequences intended for the targeting of the gene product to specific organelles and cell

compartments. These expression cassettes can then be easily transferred to the plant transformation vectors described below. The following is a description of various components of typical expression cassettes.

1. Promoters

The selection of the promoter used in expression cassettes will determine the spatial and temporal expression pattern of the transgene in the transgenic plant. Selected promoters will express transgenes in specific cell types (such as leaf epidermal cells, mesophyll cells, root cortex cells) or in specific tissues or organs (roots, leaves or flowers, for example) and the selection will reflect the desired location of accumulation of the gene product. Alternatively, the selected promoter may drive expression of the gene under various inducing conditions. Promoters vary in their strength, i.e., ability to promote transcription. Depending upon the host cell system utilized, any one of a number of suitable promoters can be used, including the gene's native promoter. The following are non-limiting examples of promoters that may be used in expression cassettes.

a. Constitutive Expression, the Ubiquitin Promoter:

Ubiquitin is a gene product known to accumulate in many cell types and its promoter has been cloned from several species for use in transgenic plants (*e.g.* sunflower - Binet *et al.* *Plant Science* **79**: 87-94 (1991); maize - Christensen *et al.* *Plant Molec. Biol.* **12**: 619-632 (1989); and *Arabidopsis* - Norris *et al.*, *Plant Mol. Biol.* **21**:895-906 (1993)). The maize ubiquitin promoter has been developed in transgenic monocot systems and its sequence and vectors constructed for monocot transformation are disclosed in the patent publication EP 0 342 926 (to Lubrizol) which is herein incorporated by reference. Taylor *et al.* (*Plant Cell Rep.* **12**: 491-495 (1993)) describe a vector (pAHC25) that comprises the maize ubiquitin promoter and first intron and its high activity in cell suspensions of numerous monocotyledons when introduced via microprojectile bombardment. The *Arabidopsis* ubiquitin promoter is ideal for use with the nucleotide sequences of the present invention. The ubiquitin promoter is suitable for gene expression in transgenic plants, both monocotyledons and dicotyledons. Suitable vectors are derivatives of pAHC25 or any of the transformation vectors described in this application, modified by the introduction of the appropriate ubiquitin promoter and/or intron sequences.

b. Constitutive Expression, the CaMV 35S Promoter:

Construction of the plasmid pCGN1761 is described in the published patent application EP 0 392 225 (Example 23), which is hereby incorporated by reference. pCGN1761 contains the "double" CaMV 35S promoter and the *tm*/transcriptional terminator with a unique *EcoRI* site between the promoter and the terminator and has a pUC-type backbone. A derivative of pCGN1761 is constructed which has a modified polylinker which includes *NotI* and *XhoI* sites in addition to the existing *EcoRI* site. This derivative is designated pCGN1761ENX. pCGN1761ENX is useful for the cloning of cDNA sequences or coding sequences (including microbial ORF sequences) within its polylinker for the purpose of their expression under the control of the 35S promoter in transgenic plants. The entire 35S promoter-coding sequence-*tm*/terminator cassette of such a construction can be excised by *HindIII*, *SphI*, *Sall*, and *XbaI* sites 5' to the promoter and *XbaI*, *BamHI* and *BglII* sites 3' to the terminator for transfer to transformation vectors such as those described below. Furthermore, the double 35S promoter fragment can be removed by 5' excision with *HindIII*, *SphI*, *Sall*, *XbaI*, or *PstI*, and 3' excision with any of the polylinker restriction sites (*EcoRI*, *NotI* or *XhoI*) for replacement with another promoter. If desired, modifications around the cloning sites can be made by the introduction of sequences that may enhance translation. This is particularly useful when overexpression is desired. For example, pCGN1761ENX may be modified by optimization of the translational initiation site as described in Example 37 of U.S. Patent No. 5,639,949, incorporated herein by reference.

c. Constitutive Expression, the Actin Promoter:

Several isoforms of actin are known to be expressed in most cell types and consequently the actin promoter is a good choice for a constitutive promoter. In particular, the promoter from the rice *Act1* gene has been cloned and characterized (McElroy *et al.* Plant Cell 2: 163-171 (1990)). A 1.3kb fragment of the promoter was found to contain all the regulatory elements required for expression in rice protoplasts. Furthermore, numerous expression vectors based on the *Act1* promoter have been constructed specifically for use in monocotyledons (McElroy *et al.* Mol. Gen. Genet. 231: 150-160 (1991)). These incorporate the *Act1*-intron 1, *Adh1* 5' flanking sequence and *Adh1*-intron 1 (from the maize alcohol dehydrogenase gene) and sequence from the CaMV 35S promoter. Vectors showing highest expression were fusions of 35S and *Act1* intron or the *Act1* 5' flanking sequence and the *Act1* intron. Optimization of sequences around the initiating ATG (of the GUS reporter

gene) also enhanced expression. The promoter expression cassettes described by McElroy *et al.* (Mol. Gen. Genet. 231: 150-160 (1991)) can be easily modified for gene expression and are particularly suitable for use in monocotyledonous hosts. For example, promoter-containing fragments is removed from the McElroy constructions and used to replace the double 35S promoter in pCGN1761ENX, which is then available for the insertion of specific gene sequences. The fusion genes thus constructed can then be transferred to appropriate transformation vectors. In a separate report, the rice *Act1* promoter with its first intron has also been found to direct high expression in cultured barley cells (Chibbar *et al.* Plant Cell Rep. 12: 506-509 (1993)).

d. Inducible Expression, the PR-1 Promoter:

The double 35S promoter in pCGN1761ENX may be replaced with any other promoter of choice that will result in suitably high expression levels. By way of example, one of the chemically regulatable promoters described in U.S. Patent No. 5,614,395 may replace the double 35S promoter. The promoter of choice is preferably excised from its source by restriction enzymes, but can alternatively be PCR-amplified using primers that carry appropriate terminal restriction sites. Should PCR-amplification be undertaken, then the promoter should be re-sequenced to check for amplification errors after the cloning of the amplified promoter in the target vector. The chemically/pathogen regulatable tobacco PR-1a promoter is cleaved from plasmid pCIB1004 (for construction, see example 21 of EP 0 332 104, which is hereby incorporated by reference) and transferred to plasmid pCGN1761ENX (Uknes *et al.*, 1992). pCIB1004 is cleaved with *NcoI* and the resultant 3' overhang of the linearized fragment is rendered blunt by treatment with T4 DNA polymerase. The fragment is then cleaved with *HindIII* and the resultant PR-1a promoter-containing fragment is gel purified and cloned into pCGN1761ENX from which the double 35S promoter has been removed. This is done by cleavage with *XhoI* and blunting with T4 polymerase, followed by cleavage with *HindIII* and isolation of the larger vector-terminator containing fragment into which the pCIB1004 promoter fragment is cloned. This generates a pCGN1761ENX derivative with the PR-1a promoter and the *tml* terminator and an intervening polylinker with unique *EcoRI* and *NotI* sites. The selected coding sequence can be inserted into this vector, and the fusion products (*i.e.* promoter-gene-terminator) can subsequently be transferred to any selected transformation vector, including those described *infra*. Various chemical regulators may be employed to induce expression of the

selected coding sequence in the plants transformed according to the present invention, including the benzothiadiazole, isonicotinic acid, and salicylic acid compounds disclosed in U.S. Patent Nos. 5,523,311 and 5,614,395.

e. Inducible Expression, an Ethanol-Inducible Promoter:

A promoter inducible by certain alcohols or ketones, such as ethanol, may also be used to confer inducible expression of a coding sequence of the present invention. Such a promoter is for example the *alcA* gene promoter from *Aspergillus nidulans* (Caddick et al. (1998) *Nat. Biotechnol* 16:177-180). In *A. nidulans*, the *alcA* gene encodes alcohol dehydrogenase I, the expression of which is regulated by the AlcR transcription factors in presence of the chemical inducer. For the purposes of the present invention, the CAT coding sequences in plasmid *palcA*:CAT comprising a *alcA* gene promoter sequence fused to a minimal 35S promoter (Caddick et al. (1998) *Nat. Biotechnol* 16:177-180) are replaced by a coding sequence of the present invention to form an expression cassette having the coding sequence under the control of the *alcA* gene promoter. This is carried out using methods well known in the art.

f. Inducible Expression, a Glucocorticoid-Inducible Promoter:

Induction of expression of a nucleic acid sequence of the present invention using systems based on steroid hormones is also contemplated. For example, a glucocorticoid-mediated induction system is used (Aoyama and Chua (1997) *The Plant Journal* 11: 605-612) and gene expression is induced by application of a glucocorticoid, for example a synthetic glucocorticoid, preferably dexamethasone, preferably at a concentration ranging from 0.1mM to 1mM, more preferably from 10mM to 100mM. For the purposes of the present invention, the luciferase gene sequences are replaced by a nucleic acid sequence of the invention to form an expression cassette having a nucleic acid sequence of the invention under the control of six copies of the GAL4 upstream activating sequences fused to the 35S minimal promoter. This is carried out using methods well known in the art. The trans-acting factor comprises the GAL4 DNA-binding domain (Keegan et al. (1986) *Science* 231: 699-704) fused to the transactivating domain of the herpes viral protein VP16 (Triezenberg et al. (1988) *Genes Devel.* 2: 718-729) fused to the hormone-binding domain of the rat glucocorticoid receptor (Picard et al. (1988) *Cell* 54: 1073-1080). The expression of the fusion protein is controlled by any promoter suitable for expression in plants known in

the art or described here. This expression cassette is also comprised in the plant comprising a nucleic acid sequence of the invention fused to the 6xGAL4/minimal promoter. Thus, tissue- or organ-specificity of the fusion protein is achieved leading to inducible tissue- or organ-specificity of the insecticidal toxin.

g. Root Specific Expression:

Another pattern of gene expression is root expression. A suitable root promoter is described by de Framond (FEBS 290: 103-106 (1991)) and also in the published patent application EP 0 452 269, which is herein incorporated by reference. This promoter is transferred to a suitable vector such as pCGN1761ENX for the insertion of a selected gene and subsequent transfer of the entire promoter-gene-terminator cassette to a transformation vector of interest.

h. Wound-Inducible Promoters:

Wound-inducible promoters may also be suitable for gene expression. Numerous such promoters have been described (e.g. Xu *et al.* Plant Molec. Biol. 22: 573-588 (1993), Logemann *et al.* Plant Cell 1: 151-158 (1989), Rohrmeier & Lehle, Plant Molec. Biol. 22: 783-792 (1993), Firek *et al.* Plant Molec. Biol. 22: 129-142 (1993), Warner *et al.* Plant J. 3: 191-201 (1993)) and all are suitable for use with the instant invention. Logemann *et al.* describe the 5' upstream sequences of the dicotyledonous potato *wun1* gene. Xu *et al.* show that a wound-inducible promoter from the dicotyledon potato (*pin2*) is active in the monocotyledon rice. Further, Rohrmeier & Lehle describe the cloning of the maize *Wip1* cDNA which is wound induced and which can be used to isolate the cognate promoter using standard techniques. Similar, Firek *et al.* and Warner *et al.* have described a wound-induced gene from the monocotyledon *Asparagus officinalis*, which is expressed at local wound and pathogen invasion sites. Using cloning techniques well known in the art, these promoters can be transferred to suitable vectors, fused to the genes pertaining to this invention, and used to express these genes at the sites of plant wounding.

i. Pith-Preferred Expression:

Patent Application WO 93/07278, which is herein incorporated by reference, describes the isolation of the maize *trpA* gene, which is preferentially expressed in pith cells. The gene sequence and promoter extending up to -1726 bp from the start of

transcription are presented. Using standard molecular biological techniques, this promoter, or parts thereof, can be transferred to a vector such as pCGN1761 where it can replace the 35S promoter and be used to drive the expression of a foreign gene in a pith-preferred manner. In fact, fragments containing the pith-preferred promoter or parts thereof can be transferred to any vector and modified for utility in transgenic plants.

j. Leaf-Specific Expression:

A maize gene encoding phosphoenol carboxylase (PEPC) has been described by Hudspeth & Grula (Plant Molec Biol 12: 579-589 (1989)). Using standard molecular biological techniques the promoter for this gene can be used to drive the expression of any gene in a leaf-specific manner in transgenic plants.

k. Pollen-Specific Expression:

WO 93/07278 describes the isolation of the maize calcium-dependent protein kinase (CDPK) gene which is expressed in pollen cells. The gene sequence and promoter extend up to 1400 bp from the start of transcription. Using standard molecular biological techniques, this promoter or parts thereof, can be transferred to a vector such as pCGN1761 where it can replace the 35S promoter and be used to drive the expression of a nucleic acid sequence of the invention in a pollen-specific manner.

2. Transcriptional Terminators

A variety of transcriptional terminators are available for use in expression cassettes. These are responsible for the termination of transcription beyond the transgene and its correct polyadenylation. Appropriate transcriptional terminators are those that are known to function in plants and include the CaMV 35S terminator, the *tm1* terminator, the nopaline synthase terminator and the pea *rbcS* E9 terminator. These can be used in both monocotyledons and dicotyledons. In addition, a gene's native transcription terminator may be used.

3. Sequences for the Enhancement or Regulation of Expression

Numerous sequences have been found to enhance gene expression from within the transcriptional unit and these sequences can be used in conjunction with the genes of this invention to increase their expression in transgenic plants.

Various intron sequences have been shown to enhance expression, particularly in monocotyledonous cells. For example, the introns of the maize *Adhl* gene have been found to significantly enhance the expression of the wild-type gene under its cognate promoter when introduced into maize cells. Intron 1 was found to be particularly effective and enhanced expression in fusion constructs with the chloramphenicol acetyltransferase gene (Callis *et al.*, Genes Develop. 1: 1183-1200 (1987)). In the same experimental system, the intron from the maize *bronze1* gene had a similar effect in enhancing expression. Intron sequences have been routinely incorporated into plant transformation vectors, typically within the non-translated leader.

A number of non-translated leader sequences derived from viruses are also known to enhance expression, and these are particularly effective in dicotyledonous cells. Specifically, leader sequences from Tobacco Mosaic Virus (TMV, the "W-sequence"), Maize Chlorotic Mottle Virus (MCMV), and Alfalfa Mosaic Virus (AMV) have been shown to be effective in enhancing expression (*e.g.* Gallie *et al.* Nucl. Acids Res. 15: 8693-8711 (1987); Skuzeski *et al.* Plant Molec. Biol. 15: 65-79 (1990)).

4. Targeting of the Gene Product Within the Cell

Various mechanisms for targeting gene products are known to exist in plants and the sequences controlling the functioning of these mechanisms have been characterized in some detail. For example, the targeting of gene products to the chloroplast is controlled by a signal sequence found at the amino terminal end of various proteins which is cleaved during chloroplast import to yield the mature protein (*e.g.* Comai *et al.* J. Biol. Chem. 263: 15104-15109 (1988)). These signal sequences can be fused to heterologous gene products to effect the import of heterologous products into the chloroplast (van den Broeck, *et al.* Nature 313: 358-363 (1985)). DNA encoding for appropriate signal sequences can be isolated from the 5' end of the cDNAs encoding the RUBISCO protein, the CAB protein, the EPSP synthase enzyme, the GS2 protein and many other proteins which are known to be chloroplast localized. *See also*, the section entitled "Expression With Chloroplast Targeting" in Example 37 of U.S. Patent No. 5,639,949.

Other gene products are localized to other organelles such as the mitochondrion and the peroxisome (*e.g.* Unger *et al.* Plant Molec. Biol. 13: 411-418 (1989)). The cDNAs encoding these products can also be manipulated to effect the targeting of heterologous gene products to these organelles. Examples of such sequences are the nuclear-encoded

ATPases and specific aspartate amino transferase isoforms for mitochondria. Targeting cellular protein bodies has been described by Rogers *et al.* (Proc. Natl. Acad. Sci. USA 82: 6512-6516 (1985)).

In addition, sequences have been characterized which cause the targeting of gene products to other cell compartments. Amino terminal sequences are responsible for targeting to the ER, the apoplast, and extracellular secretion from aleurone cells (Koehler & Ho, Plant Cell 2: 769-783 (1990)). Additionally, amino terminal sequences in conjunction with carboxy terminal sequences are responsible for vacuolar targeting of gene products (Shinshi *et al.* Plant Molec. Biol. 14: 357-368 (1990)).

By the fusion of the appropriate targeting sequences described above to transgene sequences of interest it is possible to direct the transgene product to any organelle or cell compartment. For chloroplast targeting, for example, the chloroplast signal sequence from the RUBISCO gene, the CAB gene, the EPSP synthase gene, or the GS2 gene is fused in frame to the amino terminal ATG of the transgene. The signal sequence selected should include the known cleavage site, and the fusion constructed should take into account any amino acids after the cleavage site which are required for cleavage. In some cases this requirement may be fulfilled by the addition of a small number of amino acids between the cleavage site and the transgene ATG or, alternatively, replacement of some amino acids within the transgene sequence. Fusions constructed for chloroplast import can be tested for efficacy of chloroplast uptake by *in vitro* translation of *in vitro* transcribed constructions followed by *in vitro* chloroplast uptake using techniques described by Bartlett *et al.* In: Edelman *et al.* (Eds.) Methods in Chloroplast Molecular Biology, Elsevier pp 1081-1091 (1982) and Wasmann *et al.* Mol. Gen. Genet. 205: 446-453 (1986). These construction techniques are well known in the art and are equally applicable to mitochondria and peroxisomes.

The above-described mechanisms for cellular targeting can be utilized not only in conjunction with their cognate promoters, but also in conjunction with heterologous promoters so as to effect a specific cell-targeting goal under the transcriptional regulation of a promoter that has an expression pattern different to that of the promoter from which the targeting signal derives.

Example 24: Construction of Plant Transformation Vectors

Numerous transformation vectors available for plant transformation are known to those of ordinary skill in the plant transformation arts, and the genes pertinent to this invention can be used in conjunction with any such vectors. The selection of vector will depend upon the preferred transformation technique and the target species for transformation. For certain target species, different antibiotic or herbicide selection markers may be preferred. Selection markers used routinely in transformation include the *nptII* gene, which confers resistance to kanamycin and related antibiotics (Messing & Vierra, Gene 19: 259-268 (1982); Bevan et al., Nature 304:184-187 (1983)), the *bar* gene, which confers resistance to the herbicide phosphinothricin (White et al., Nucl. Acids Res 18: 1062 (1990), Spencer et al. Theor. Appl. Genet 79: 625-631 (1990)), the *hph* gene, which confers resistance to the antibiotic hygromycin (Blochinger & Diggelmann, Mol Cell Biol 4: 2929-2931), and the *dhfr* gene, which confers resistance to methatrexate (Bourouis et al., EMBO J. 2(7): 1099-1104 (1983)), and the EPSPS gene, which confers resistance to glyphosate (U.S. Patent Nos. 4,940,935 and 5,188,642).

1. Vectors Suitable for *Agrobacterium* Transformation

Many vectors are available for transformation using *Agrobacterium tumefaciens*. These typically carry at least one T-DNA border sequence and include vectors such as pBIN19 (Bevan, Nucl. Acids Res. (1984)) and pXYZ. Below, the construction of two typical vectors suitable for *Agrobacterium* transformation is described.

a. pCIB200 and pCIB2001:

The binary vectors pCIB200 and pCIB2001 are used for the construction of recombinant vectors for use with *Agrobacterium* and are constructed in the following manner. pTJS75kan is created by *NarI* digestion of pTJS75 (Schmidhauser & Helinski, J. Bacteriol. 164: 446-455 (1985)) allowing excision of the tetracycline-resistance gene, followed by insertion of an *AccI* fragment from pUC4K carrying an NPTII (Messing & Vierra, Gene 19: 259-268 (1982); Bevan et al., Nature 304: 184-187 (1983); McBride et al., Plant Molecular Biology 14: 266-276 (1990)). *XhoI* linkers are ligated to the *EcoRV* fragment of PCIB7 which contains the left and right T-DNA borders, a plant selectable *nos/nptII* chimeric gene and the pUC polylinker (Rothstein et al., Gene 53: 153-161 (1987)), and the *XhoI*-

digested fragment are cloned into *Sall*-digested pTJS75kan to create pCIB200 (see also EP 0 332 104, example 19). pCIB200 contains the following unique polylinker restriction sites: *EcoRI*, *SstI*, *KpnI*, *BglII*, *XbaI*, and *Sall*. pCIB2001 is a derivative of pCIB200 created by the insertion into the polylinker of additional restriction sites. Unique restriction sites in the polylinker of pCIB2001 are *EcoRI*, *SstI*, *KpnI*, *BglII*, *XbaI*, *Sall*, *MluI*, *BclI*, *AvrII*, *ApaI*, *HpaI*, and *StuI*. pCIB2001, in addition to containing these unique restriction sites also has plant and bacterial kanamycin selection, left and right T-DNA borders for *Agrobacterium*-mediated transformation, the RK2-derived *trfA* function for mobilization between *E. coli* and other hosts, and the *OriT* and *OriV* functions also from RK2. The pCIB2001 polylinker is suitable for the cloning of plant expression cassettes containing their own regulatory signals.

b. pCIB10 and Hygromycin Selection Derivatives thereof:

The binary vector pCIB10 contains a gene encoding kanamycin resistance for selection in plants and T-DNA right and left border sequences and incorporates sequences from the wide host-range plasmid pRK252 allowing it to replicate in both *E. coli* and *Agrobacterium*. Its construction is described by Rothstein *et al.* (Gene 53: 153-161 (1987)). Various derivatives of pCIB10 are constructed which incorporate the gene for hygromycin B phosphotransferase described by Gritz *et al.* (Gene 25: 179-188 (1983)). These derivatives enable selection of transgenic plant cells on hygromycin only (pCIB743), or hygromycin and kanamycin (pCIB715, pCIB717).

2. Vectors Suitable for non-*Agrobacterium* Transformation

Transformation without the use of *Agrobacterium tumefaciens* circumvents the requirement for T-DNA sequences in the chosen transformation vector and consequently vectors lacking these sequences can be utilized in addition to vectors such as the ones described above which contain T-DNA sequences. Transformation techniques that do not rely on *Agrobacterium* include transformation via particle bombardment, protoplast uptake (e.g. PEG and electroporation) and microinjection. The choice of vector depends largely on the preferred selection for the species being transformed. Below, the construction of typical vectors suitable for non-*Agrobacterium* transformation is described.

a. pCIB3064:

pCIB3064 is a pUC-derived vector suitable for direct gene transfer techniques in combination with selection by the herbicide basta (or phosphinothricin). The plasmid pCIB246 comprises the CaMV 35S promoter in operational fusion to the *E. coli* GUS gene and the CaMV 35S transcriptional terminator and is described in the PCT published application WO 93/07278. The 35S promoter of this vector contains two ATG sequences 5' of the start site. These sites are mutated using standard PCR techniques in such a way as to remove the ATGs and generate the restriction sites *SspI* and *PvuII*. The new restriction sites are 96 and 37 bp away from the unique *SalI* site and 101 and 42 bp away from the actual start site. The resultant derivative of pCIB246 is designated pCIB3025. The GUS gene is then excised from pCIB3025 by digestion with *SalI* and *SacI*, the termini rendered blunt and religated to generate plasmid pCIB3060. The plasmid pJIT82 is obtained from the John Innes Centre, Norwich and the a 400 bp *SmaI* fragment containing the *bar* gene from *Streptomyces viridochromogenes* is excised and inserted into the *HpaI* site of pCIB3060 (Thompson *et al.* EMBO J 6: 2519-2523 (1987)). This generated pCIB3064, which comprises the *bar* gene under the control of the CaMV 35S promoter and terminator for herbicide selection, a gene for ampicillin resistance (for selection in *E. coli*) and a polylinker with the unique sites *SphI*, *PstI*, *HindIII*, and *BamHI*. This vector is suitable for the cloning of plant expression cassettes containing their own regulatory signals.

b. pSOG19 and pSOG35:

pSOG35 is a transformation vector that utilizes the *E. coli* gene dihydrofolate reductase (DHFR) as a selectable marker conferring resistance to methotrexate. PCR is used to amplify the 35S promoter (-800 bp), intron 6 from the maize Adh1 gene (-550 bp) and 18 bp of the GUS untranslated leader sequence from pSOG10. A 250-bp fragment encoding the *E. coli* dihydrofolate reductase type II gene is also amplified by PCR and these two PCR fragments are assembled with a *SacI-PstI* fragment from pB1221 (Clontech) which comprises the pUC19 vector backbone and the nopaline synthase terminator. Assembly of these fragments generates pSOG19 which contains the 35S promoter in fusion with the intron 6 sequence, the GUS leader, the DHFR gene and the nopaline synthase terminator. Replacement of the GUS leader in pSOG19 with the leader sequence from Maize Chlorotic Mottle Virus (MCMV) generates the vector pSOG35. pSOG19 and pSOG35 carry the pUC gene for ampicillin resistance and have *HindIII*, *SphI*, *PstI* and *EcoRI* sites available for the cloning of foreign substances.

3. Vector Suitable for Chloroplast Transformation

For expression of a nucleotide sequence of the present invention in plant plastids, plastid transformation vector pPH143 (WO 97/32011, example 36) is used. The nucleotide sequence is inserted into pPH143 thereby replacing the PROTOX coding sequence. This vector is then used for plastid transformation and selection of transformants for spectinomycin resistance. Alternatively, the nucleotide sequence is inserted in pPH143 so that it replaces the *aadH* gene. In this case, transformants are selected for resistance to PROTOX inhibitors.

Example 25: Transformation

Once a nucleic acid sequence of the invention has been cloned into an expression system, it is transformed into a plant cell. Methods for transformation and regeneration of plants are well known in the art. For example, Ti plasmid vectors have been utilized for the delivery of foreign DNA, as well as direct DNA uptake, liposomes, electroporation, microinjection, and microprojectiles. In addition, bacteria from the genus *Agrobacterium* can be utilized to transform plant cells. Below are descriptions of representative techniques for transforming both dicotyledonous and monocotyledonous plants, as well as a representative plastid transformation technique.

1. Transformation of Dicotyledons

Transformation techniques for dicotyledons are well known in the art and include *Agrobacterium*-based techniques and techniques that do not require *Agrobacterium*. Non-*Agrobacterium* techniques involve the uptake of exogenous genetic material directly by protoplasts or cells. This can be accomplished by PEG or electroporation mediated uptake, particle bombardment-mediated delivery, or microinjection. Examples of these techniques are described by Paszkowski *et al.*, EMBO J **3**: 2717-2722 (1984), Potrykus *et al.*, Mol. Gen. Genet. **199**: 169-177 (1985), Reich *et al.*, Biotechnology **4**: 1001-1004 (1986), and Klein *et al.*, Nature **327**: 70-73 (1987). In each case the transformed cells are regenerated to whole plants using standard techniques known in the art.

Agrobacterium-mediated transformation is a preferred technique for transformation of dicotyledons because of its high efficiency of transformation and its broad utility with many

different species. *Agrobacterium* transformation typically involves the transfer of the binary vector carrying the foreign DNA of interest (e.g. pCIB200 or pCIB2001) to an appropriate *Agrobacterium* strain which may depend of the complement of *vir* genes carried by the host *Agrobacterium* strain either on a co-resident Ti plasmid or chromosomally (e.g. strain CIB542 for pCIB200 and pCIB2001 (Uknes *et al.* Plant Cell 5: 159-169 (1993)). The transfer of the recombinant binary vector to *Agrobacterium* is accomplished by a triparental mating procedure using *E. coli* carrying the recombinant binary vector, a helper *E. coli* strain which carries a plasmid such as pRK2013 and which is able to mobilize the recombinant binary vector to the target *Agrobacterium* strain. Alternatively, the recombinant binary vector can be transferred to *Agrobacterium* by DNA transformation (Höfgen & Willmitzer, Nucl. Acids Res. 16: 9877 (1988)).

Transformation of the target plant species by recombinant *Agrobacterium* usually involves co-cultivation of the *Agrobacterium* with explants from the plant and follows protocols well known in the art. Transformed tissue is regenerated on selectable medium carrying the antibiotic or herbicide resistance marker present between the binary plasmid T-DNA borders.

Another approach to transforming plant cells with a gene involves propelling inert or biologically active particles at plant tissues and cells. This technique is disclosed in U.S. Patent Nos. 4,945,050, 5,036,006, and 5,100,792 all to Sanford *et al.* Generally, this procedure involves propelling inert or biologically active particles at the cells under conditions effective to penetrate the outer surface of the cell and afford incorporation within the interior thereof. When inert particles are utilized, the vector can be introduced into the cell by coating the particles with the vector containing the desired gene. Alternatively, the target cell can be surrounded by the vector so that the vector is carried into the cell by the wake of the particle. Biologically active particles (e.g., dried yeast cells, dried bacterium or a bacteriophage, each containing DNA sought to be introduced) can also be propelled into plant cell tissue.

2. Transformation of Monocotyledons

Transformation of most monocotyledon species has now also become routine. Preferred techniques include direct gene transfer into protoplasts using PEG or electroporation techniques, and particle bombardment into callus tissue. Transformations can be undertaken with a single DNA species or multiple DNA species (*i.e.* co-

transformation) and both these techniques are suitable for use with this invention. Co-transformation may have the advantage of avoiding complete vector construction and of generating transgenic plants with unlinked loci for the gene of interest and the selectable marker, enabling the removal of the selectable marker in subsequent generations, should this be regarded desirable. However, a disadvantage of the use of co-transformation is the less than 100% frequency with which separate DNA species are integrated into the genome (Schocher *et al.* *Biotechnology* 4: 1093-1096 (1986)).

Patent Applications EP 0 292 435, EP 0 392 225, and WO 93/07278 describe techniques for the preparation of callus and protoplasts from an elite inbred line of maize, transformation of protoplasts using PEG or electroporation, and the regeneration of maize plants from transformed protoplasts. Gordon-Kamm *et al.* (*Plant Cell* 2: 603-618 (1990)) and Fromm *et al.* (*Biotechnology* 8: 833-839 (1990)) have published techniques for transformation of A188-derived maize line using particle bombardment. Furthermore, WO 93/07278 and Koziel *et al.* (*Biotechnology* 11: 194-200 (1993)) describe techniques for the transformation of elite inbred lines of maize by particle bombardment. This technique utilizes immature maize embryos of 1.5-2.5 mm length excised from a maize ear 14-15 days after pollination and a PDS-1000He Biolistics device for bombardment.

Transformation of rice can also be undertaken by direct gene transfer techniques utilizing protoplasts or particle bombardment. Protoplast-mediated transformation has been described for *Japonica*-types and *Indica*-types (Zhang *et al.* *Plant Cell Rep* 7: 379-384 (1988); Shimamoto *et al.* *Nature* 338: 274-277 (1989); Datta *et al.* *Biotechnology* 8: 736-740 (1990)). Both types are also routinely transformable using particle bombardment (Christou *et al.* *Biotechnology* 9: 957-962 (1991)). Furthermore, WO 93/21335 describes techniques for the transformation of rice via electroporation.

Patent Application EP 0 332 581 describes techniques for the generation, transformation and regeneration of *Pooideae* protoplasts. These techniques allow the transformation of *Dactylis* and wheat. Furthermore, wheat transformation has been described by Vasil *et al.* (*Biotechnology* 10: 667-674 (1992)) using particle bombardment into cells of type C long-term regenerable callus, and also by Vasil *et al.* (*Biotechnology* 11: 1553-1558 (1993)) and Weeks *et al.* (*Plant Physiol.* 102: 1077-1084 (1993)) using particle bombardment of immature embryos and immature embryo-derived callus. A preferred technique for wheat transformation, however, involves the transformation of wheat by particle bombardment of immature embryos and includes either a high sucrose or a high

maltose step prior to gene delivery. Prior to bombardment, any number of embryos (0.75-1 mm in length) are plated onto MS medium with 3% sucrose (Murashiga & Skoog, *Physiologia Plantarum* 15: 473-497 (1962)) and 3 mg/l 2,4-D for induction of somatic embryos, which is allowed to proceed in the dark. On the chosen day of bombardment, embryos are removed from the induction medium and placed onto the osmoticum (*i.e.* induction medium with sucrose or maltose added at the desired concentration, typically 15%). The embryos are allowed to plasmolyze for 2-3 h and are then bombarded. Twenty embryos per target plate is typical, although not critical. An appropriate gene-carrying plasmid (such as pCIB3064 or pSG35) is precipitated onto micrometer size gold particles using standard procedures. Each plate of embryos is shot with the DuPont Biolistics® helium device using a burst pressure of ~1000-psi using a standard 80-mesh-screen. After bombardment, the embryos are placed back into the dark to recover for about 24 h (still on osmoticum). After 24 hrs, the embryos are removed from the osmoticum and placed back onto induction medium where they stay for about a month before regeneration. Approximately one month later the embryo explants with developing embryogenic callus are transferred to regeneration medium (MS + 1 mg/liter NAA, 5 mg/liter GA), further containing the appropriate selection agent (10 mg/l basta in the case of pCIB3064 and 2 mg/l methotrexate in the case of pSOG35). After approximately one month, developed shoots are transferred to larger sterile containers known as "GA7s" which contain half-strength MS, 2% sucrose, and the same concentration of selection agent.

Transformation of monocotyledons using *Agrobacterium* has also been described. See, WO 94/00977 and U.S. Patent No. 5,591,616, both of which are incorporated herein by reference.

3. Transformation of Plastids

Seeds of *Nicotiana tabacum* c.v. 'Xanthi nc' are germinated seven per plate in a 1" circular array on T agar medium and bombarded 12-14 days after sowing with 1 μ m tungsten particles (M10, Biorad, Hercules, CA) coated with DNA from plasmids pPH143 and pPH145 essentially as described (Svab, Z. and Maliga, P. (1993) *PNAS* 90, 913-917). Bombarded seedlings are incubated on T medium for two days after which leaves are excised and placed abaxial side up in bright light (350-500 μ mol photons/m²/s) on plates of RMOP medium (Svab, Z., Hajdukiewicz, P. and Maliga, P. (1990) *PNAS* 87, 8526-8530) containing 500 μ g/ml spectinomycin dihydrochloride (Sigma, St. Louis, MO). Resistant

shoots appearing underneath the bleached leaves three to eight weeks after bombardment are subcloned onto the same selective medium, allowed to form callus, and secondary shoots isolated and subcloned. Complete segregation of transformed plastid genome copies (homoplasmy) in independent subclones is assessed by standard techniques of Southern blotting (Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor). BamHI/EcoRI-digested total cellular DNA (Mettler, I. J. (1987) *Plant Mol Biol Reporter* 5, 346-349) is separated on 1% Tris-borate (TBE) agarose gels, transferred to nylon membranes (Amersham) and probed with ³²P-labeled random primed DNA sequences corresponding to a 0.7 kb BamHI/HindIII DNA fragment from pC8 containing a portion of the *rps7/12* plastid targeting sequence. Homoplasmy shoots are rooted aseptically on spectinomycin-containing-MS/IBA medium (McBride, K. E. et al. (1994) *PNAS* 91, 7301-7305) and transferred to the greenhouse.

E. Breeding and Seed Production

Example 26: Breeding

The plants obtained via transformation with a nucleic acid sequence of the present invention can be any of a wide variety of plant species, including those of monocots and dicots; however, the plants used in the method of the invention are preferably selected from the list of agronomically important target crops set forth *supra*. The expression of a gene of the present invention in combination with other characteristics important for production and quality can be incorporated into plant lines through breeding. Breeding approaches and techniques are known in the art. See, for example, Welsh J. R., *Fundamentals of Plant Genetics and Breeding*, John Wiley & Sons, NY (1981); *Crop Breeding*, Wood D. R. (Ed.) American Society of Agronomy Madison, Wisconsin (1983); Mayo O., *The Theory of Plant Breeding*, Second Edition, Clarendon Press, Oxford (1987); Singh, D.P., *Breeding for Resistance to Diseases and Insect Pests*, Springer-Verlag, NY (1986); and Wricke and Weber, *Quantitative Genetics and Selection Plant Breeding*, Walter de Gruyter and Co., Berlin (1986).

The genetic properties engineered into the transgenic seeds and plants described above are passed on by sexual reproduction or vegetative growth and can thus be maintained and propagated in progeny plants. Generally said maintenance and propagation

make use of known agricultural methods developed to fit specific purposes such as tilling, sowing or harvesting. Specialized processes such as hydroponics or greenhouse technologies can also be applied. As the growing crop is vulnerable to attack and damages caused by insects or infections as well as to competition by weed plants, measures are undertaken to control weeds, plant diseases, insects, nematodes, and other adverse conditions to improve yield. These include mechanical measures such a tillage of the soil or removal of weeds and infected plants, as well as the application of agrochemicals such as herbicides, fungicides, gametocides, nematocides, growth regulants, ripening agents and insecticides.

Use of the advantageous genetic properties of the transgenic plants and seeds according to the invention can further be made in plant breeding, which aims at the development of plants with improved properties such as tolerance of pests, herbicides, or stress, improved nutritional value, increased yield, or improved structure causing less loss from lodging or shattering. The various breeding steps are characterized by well-defined human intervention such as selecting the lines to be crossed, directing pollination of the parental lines, or selecting appropriate progeny plants. Depending on the desired properties, different breeding measures are taken. The relevant techniques are well known in the art and include but are not limited to hybridization, inbreeding, backcross breeding, multiline breeding, variety blend, interspecific hybridization, aneuploid techniques, etc. Hybridization techniques also include the sterilization of plants to yield male or female sterile plants by mechanical, chemical, or biochemical means. Cross pollination of a male sterile plant with pollen of a different line assures that the genome of the male sterile but female fertile plant will uniformly obtain properties of both parental lines. Thus, the transgenic seeds and plants according to the invention can be used for the breeding of improved plant lines, that for example, increase the effectiveness of conventional methods such as herbicide or pestidice treatment or allow one to dispense with said methods due to their modified genetic properties. Alternatively new crops with improved stress tolerance can be obtained, which, due to their optimized genetic "equipment", yield harvested product of better quality than products that were not able to tolerate comparable adverse developmental conditions.

Example 27: Seed Production

In seed production, germination quality and uniformity of seeds are essential product characteristics, whereas germination quality and uniformity of seeds harvested and sold by the farmer is not important. As it is difficult to keep a crop free from other crop and weed seeds, to control seedborne diseases, and to produce seed with good germination, fairly extensive and well-defined seed production practices have been developed by seed producers, who are experienced in the art of growing, conditioning and marketing of pure seed. Thus, it is common practice for the farmer to buy certified seed meeting specific quality standards instead of using seed harvested from his own crop. Propagation material to be used as seeds is customarily treated with a protectant coating comprising herbicides, insecticides, fungicides, bactericides, nematocides, molluscicides, or mixtures thereof. Customarily used protectant coatings comprise compounds such as captan, carboxin, thiram (TMTD®), methalaxyl (Apron®), and pirimiphos-methyl (Actellic®). If desired, these compounds are formulated together with further carriers, surfactants or application-promoting adjuvants customarily employed in the art of formulation to provide protection against damage caused by bacterial, fungal or animal pests. The protectant coatings may be applied by impregnating propagation material with a liquid formulation or by coating with a combined wet or dry formulation. Other methods of application are also possible such as treatment directed at the buds or the fruit.

It is a further aspect of the present invention to provide new agricultural methods, such as the methods exemplified above, which are characterized by the use of transgenic plants, transgenic plant material, or transgenic seed according to the present invention.

The seeds may be provided in a bag, container or vessel comprised of a suitable packaging material, the bag or container capable of being closed to contain seeds. The bag, container or vessel may be designed for either short term or long term storage, or both, of the seed. Examples of a suitable packaging material include paper, such as kraft paper, rigid or pliable plastic or other polymeric material, glass or metal. Desirably the bag, container, or vessel is comprised of a plurality of layers of packaging materials, of the same or differing type. In one embodiment the bag, container or vessel is provided so as to exclude or limit water and moisture from contacting the seed. In one example, the bag, container or vessel is sealed, for example heat sealed, to prevent water or moisture from entering. In another embodiment water absorbent materials are placed between or adjacent to packaging material layers. In yet another embodiment the bag, container or

vessel, or packaging material of which it is comprised is treated to limit, suppress or prevent disease, contamination or other adverse affects of storage or transport of the seed. An example of such treatment is sterilization, for example by chemical means or by exposure to radiation. Comprised by the present invention is a commercial bag comprising seed of a transgenic plant comprising a gene of the present invention that is expressed in said transformed plant at higher levels than in a wild type plant, together with a suitable carrier, together with label instructions for the use thereof for conferring broad spectrum disease resistance to plants.

The above disclosed embodiments are illustrative. This disclosure of the invention will place one skilled in the art in possession of many variations of the invention. All such obvious and foreseeable variations are intended to be encompassed by the appended claims.

**BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURES**

INTERNATIONAL FORM

TO

VIABILITY STATEMENT

Novartis Corp.
c/o Novartis AG
P. O. Box 12257
Research Triangle Park, NC 27709

issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

NAME AND ADDRESS OF THE PARTY TO WHOM
THE VIABILITY STATEMENT IS ISSUED

I. DEPOSITOR Name: Novartis Corp. c/o Novartis AG Address: P. O. Box 12257 Research Triangle Park, NC 27709	II. IDENTIFICATION OF THE MICROORGANISM Depositor's taxonomic designation and accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: Bacteria sp. NRRL B-21883 Date of: November 12, 1997 <input checked="" type="checkbox"/> : Original Deposit <input type="checkbox"/> : New Deposit <input type="checkbox"/> : Repropagation of Original Deposit		
III. (a) VIABILITY STATEMENT Deposit was found: <input checked="" type="checkbox"/> Viable <input type="checkbox"/> Nonviable on November 14, 1997 (Date) International Depositary Authority's preparation was found viable on November 25, 1997 (Date) ¹			
III. (b) DEPOSITOR'S EQUIVALENCY DECLARATION Depositor determined the International Depositary Authority's preparation was <input type="checkbox"/> Equivalent <input type="checkbox"/> Not equivalent to deposit on _____ (Date) Signature of Depositor _____			
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST WAS PERFORMED (Depositors/Depositary)⁴ _____			
V. INTERNATIONAL DEPOSITARY AUTHORITY <table border="0"> <tr> <td data-bbox="315 1623 792 1764"> Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A. </td> <td data-bbox="792 1623 1300 1764"> Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>P. J. [Signature]</i> Date: 12-3-97 </td> </tr> </table>		Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>P. J. [Signature]</i> Date: 12-3-97
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>P. J. [Signature]</i> Date: 12-3-97		

¹ Indicate the date of the original deposit or when a new deposit has been made.

² Mark with a cross the applicable box.

³ In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.

⁴ Fill in if the information has been requested.

**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSE OF PATENT PROCEDURES**

INTERNATIONAL FORM

TO
Novartis Corp.
c/o Novartis AG
P. O. Box 12257
Research Triangle Park, NC 27709

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

**NAME AND ADDRESS
OF DEPOSITOR**

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: Bacteria sp. pCTB 9369	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-21883
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by:	
<input checked="" type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on November 12, 1997 (date of the original deposit).	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I. above was received by this International Depositary Authority on _____ (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>[Signature]</i> Date: 12-1-97

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

DEPOSITS

<u>Clone</u>	<u>Accession number</u>	<u>Date of Deposit</u>
pCIB9369	NRRL B-21883	November 12, 1997

What is claimed is:

1. An isolated nucleic acid molecule comprising:
 - (a) a nucleotide sequence substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:14; or
 - (b) a nucleotide sequence isocoding with the nucleotide sequence of (a);wherein expression of said nucleic acid molecule results in at least one toxin that is active against insects.
2. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is isocoding with a nucleotide sequence substantially similar to nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14.
3. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is substantially similar to nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14.
4. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence encodes an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 3, 5, 7, 9, 11, 13, and 15.
5. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence comprises nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14.
6. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is substantially similar to nucleotides 569-979 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:8, or SEQ ID NO:12.

7. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence encodes the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:9, or SEQ ID NO:13.
8. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is substantially similar to nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:6, SEQ ID NO:10, or SEQ ID NO:14.
9. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence encodes the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, or SEQ ID NO:15.
10. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence comprises the approximately 3.0 kb DNA fragment comprised in pCIB9369 (NRRL B-21883).
11. An isolated nucleic acid molecule according to claim 1, wherein the toxin is active against *Plutella xylostella*.
12. An isolated nucleic acid molecule comprising a 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair nucleotide portion of a nucleotide sequence selected from the group consisting of: nucleotides 569-979 of SEQ ID NO:1, nucleotides 1045-2334 of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, and SEQ ID NO:14, wherein expression of said nucleic acid molecule results in at least one toxin that is active against insects.
13. A chimeric gene comprising a heterologous promoter sequence operatively linked to the nucleic acid molecule of claim 1 or claim 12.
14. A recombinant vector comprising the chimeric gene of claim 13.
15. A host cell comprising the chimeric gene of claim 13.

16. A host cell according to claim 15, which is a bacterial cell.
17. A host cell according to claim 15, which is a yeast cell.
18. A host cell according to claim 15, which is a plant cell.
19. A plant comprising the plant cell of claim 18.
20. A plant according to claim 19, which is maize.
21. A toxin produced by expression of a DNA molecule according to claim 1 or claim 12.
22. A toxin according to claim 21, wherein said toxin is active against *Plutella xylostella*.
23. A toxin according to claim 21, wherein said toxin is produced by the *E. coli* strain designated as NRRL accession number B-21883.
24. A toxin according to claim 21, wherein said toxin comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs:2, 3, 5, 7, 9, 11, 13, and 15.
25. A toxin according to claim 24, wherein said toxin comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs:2, 5, 9, and 13.
26. A toxin according to claim 24, wherein said toxin comprises an amino acid sequence selected from the group consisting of: SEQ ID NOs:3, 7, 11, and 15.
27. A composition comprising an insecticidally effective amount of a toxin according to claim 21.
28. A method of producing a toxin that is active against insects, comprising:
 - (a) obtaining a host cell according to claim 15; and
 - (b) expressing the nucleic acid molecule in said cell, which results in at least one toxin that is active against insects.

29. A method of producing an insect-resistant plant, comprising introducing a nucleic acid molecule according to claim 1 or claim 12 into said plant, wherein said nucleic acid molecule is expressible in said plant in an effective amount to control an insect.

30. The method of claim 29, wherein the insect is *Plutella xylostella*.

31. A method of controlling an insect comprising delivering to the insect an effective amount of a toxin according to claim 21.

32. The method of claim 31, wherein the insect is *Plutella xylostella*.

33. The method of claim 32, wherein the toxin is delivered to the insect orally.

34. A method for mutagenizing a nucleic acid molecule according to claim 1 or claim 12, wherein the nucleic acid molecule has been cleaved into population of double-stranded random fragments of a desired size, comprising:

- (a) adding to the population of double-stranded random fragments one or more single- or double-stranded oligonucleotides, wherein said oligonucleotides each comprise an area of identity and an area of heterology to a double-stranded template polynucleotide;
- (b) denaturing the resultant mixture of double-stranded random fragments and oligonucleotides into single-stranded fragments;
- (c) incubating the resultant population of single-stranded fragments with a polymerase under conditions which result in the annealing of said single-stranded fragments at said areas of identity to form pairs of annealed fragments, said areas of identity being sufficient for one member of a pair to prime replication of the other, thereby forming a mutagenized double-stranded polynucleotide; and
- (d) repeating the second and third steps for at least two further cycles, wherein the resultant mixture in the second step of a further cycle includes the mutagenized double-stranded polynucleotide from the third step of the previous cycle, and wherein the further cycle forms a further mutagenized double-stranded polynucleotide.

SEQUENCE LISTING

<110> Novartis AG

<120> NOVEL INSECTICIDAL TOXINS FROM XENORHABDUS NEMATOPHILUS
AND NUCLEIC ACID SEQUENCES CODING THEREFOR

<130> 30472/A/CGC1992

<140>

<141>

<160> 15

<170> PatentIn Ver. 2.0

<210> 1

<211> 2978

<212> DNA

<213> Xenorhabdus nematophilus

<220>

<221> CDS

<222> (569)..(976)

<223> orf1

<220>

<221> CDS

<222> (1045)..(2331)

<223> JHE-like orf2

<220>

<223> pCIB9369

<400> 1

atcgatgtga cggcagagta tttttattcc tgtaaactga cgacaatgca tttctaagat 60

atcaatataa taatgataaa tttattgatc atatatctgt tatattttga ttgaaaatta 120

ttgaatatac ctcttgact aaattcatta catTTTTTTT actttaaaca acattaaatt 180

cacacataat acagcttaaa tataacatgt gatatatatt atgattataa aaaacattaa 240

aataaataat acgccacata tattaacaat atctaattac tgatgatact attttctgag 300

tatatataaa tcttaaagaa aataattatt ttttatattt cacatcaatt taaaatctgc 360

ttagaatgcc ccccggtatc acaagaaaac aaaatcattc aagtaatata atagagttaa 420

atTTTAAAAA aacatgtata acaaaatata tagacaatta tacatgtaaa tgacagacaa 480

ctgacaaaaac atagcaaaaa aacgccttaa atattaaggt atcaaaacaa tatatcagac 540

tatcttaaat ctaataggag aatccctc atg att aca ata cat atc agt ggt 592

Met Ile Thr Ile His Ile Ser Gly

1

5

ggt agt gta aca att aat aac aat ata gta aca gaa act gat gtc caa 640

Gly Ser Val Thr Ile Asn Asn Ile Val Thr Glu Thr Asp Val Gln

10

15

20

aat aca ccc gct tca gcg cct tta tca att act aat ttt agg gat atg 688

Asn Thr Pro Ala Ser Ala Pro Leu Ser Ile Thr Asn Phe Arg Asp Met

25

30

35

40

aca ata gaa cct cat tca tct gtt gag gcg ata aga acc gat aca ccg 736
 Thr Ile Glu Pro His Ser Ser Val Glu Ala Ile Arg Thr Asp Thr Pro
 45 50 55
 att att cct gaa tca cga cca aat tac tat gtt gct aat tct ggc ccg 784
 Ile Ile Pro Glu Ser Arg Pro Asn Tyr Tyr Val Ala Asn Ser Gly Pro
 60 65 70
 gcc tca tca gtc aga gct gtt ttc tat tgg tcc cac tct ttt aca tca 832
 Ala Ser Ser Val Arg Ala Val Phe Tyr Trp Ser His Ser Phe Thr Ser
 75 80 85
 gaa tgg ttt gaa tct tcc tct att att gta aaa gca ggc gaa gac gga 880
 Glu Trp Phe Glu Ser Ser Ser Ile Ile Val Lys Ala Gly Glu Asp Gly
 90 95 100
 gtc tta cat tca ccg ggt aat tct tta tat tac agc aag gtt gta att 928
 Val Leu His Ser Pro Gly Asn Ser Leu Tyr Tyr Ser Lys Val Val Ile
 105 110 115 120
 tat aac gat aca gac aaa cgt gct ttt gtt acc ggc tac aat cta taa 976
 Tyr Asn Asp Thr Asp Lys Arg Ala Phe Val Thr Gly Tyr Asn Leu
 125 130 135
 taacgcagaa atacaatcca tatttccaat gaatttcaaa taacatcctt aaggcaagaa 1036
 acaaaatc atg aat aat gaa ccg atg aat act aat gaa tca caa gct tca 1086
 Met Asn Asn Glu Pro Met Asn Thr Asn Glu Ser Gln Ala Ser
 140 145 150
 gag ata gta ccc tca atg aat gaa tct ata tta gca gca cct tat tca 1134
 Glu Ile Val Pro Ser Met Asn Glu Ser Ile Leu Ala Ala Pro Tyr Ser
 155 160 165
 att tct aca cct aat tat gaa tgg gat atg tca tca ata ata aaa gat 1182
 Ile Ser Thr Pro Asn Tyr Glu Trp Asp Met Ser Ser Ile Ile Lys Asp
 170 175 180
 gct att att ggt ggt ata ggc ttt att cct ggt ccg ggc tca gca ata 1230
 Ala Ile Ile Gly Gly Ile Gly Phe Ile Pro Gly Pro Gly Ser Ala Ile
 185 190 195
 tca ttt ttg tta ggg tta ttt tgg cca caa caa acc gac aat act tgg 1278
 Ser Phe Leu Leu Gly Leu Phe Trp Pro Gln Gln Thr Asp Asn Thr Trp
 200 205 210
 gag caa att ctc caa aaa gta gaa caa atg atc gag caa gcc aat ctc 1326
 Glu Gln Ile Leu Gln Lys Val Glu Gln Met Ile Glu Gln Ala Asn Leu
 215 220 225 230
 aaa act att caa gga ata ttg aac ggc gat ata caa gaa att aaa ggc 1374
 Lys Thr Ile Gln Gly Ile Leu Asn Gly Asp Ile Gln Glu Ile Lys Gly
 235 240 245
 aaa atg gaa cat gtg caa ttc atg cta gaa tcc tca cct ggc act caa 1422
 Lys Met Glu His Val Gln Phe Met Leu Glu Ser Ser Pro Gly Thr Gln
 250 255 260
 gaa agc cat gac gca tac atg ttt ctg gcg aga tat ctg gtc agt ata 1470
 Glu Ser His Asp Ala Tyr Met Phe Leu Ala Arg Tyr Leu Val Ser Ile
 265 270 275
 gac gaa aaa ttc aag tct ttt gat aac aaa aca aat tat caa att ctt 1518
 Asp Glu Lys Phe Lys Ser Phe Asp Asn Lys Thr Asn Tyr Gln Ile Leu
 280 285 290

```

ccc atg tat acc aat acg att atg tta caa gcc cct tat tgg aaa atg 1566
Pro Met Tyr Thr Asn Thr Ile Met Leu Gln Ala Pro Tyr Trp Lys Met
295          300          305          310

ggt ata gag aga aaa gat gag atc aaa cta aca gat ata gaa gtt aat 1614
Gly Ile Glu Arg Lys Asp Glu Ile Lys Leu Thr Asp Ile Glu Val Asn
          315          320          325

gaa tta aaa gag ctg ata gga aaa tta tct acc agc gcc gat aaa tat 1662
Glu Leu Lys Glu Leu Ile Gly Lys Leu Ser Thr Ser Ala Asp Lys Tyr
          330          335          340

att cat gat gtc tat act cgt gaa tat gat aat gcg atg aac act tca 1710
Ile His Asp Val Tyr Thr Arg Glu Tyr Asp Asn Ala Met Asn Thr Ser
          345          350          355

aca gca gca aat atc acc aat aat tta tta tct gta aga ggc tat tgt 1758
Thr Ala Ala Asn Ile Thr Asn Asn Leu Leu Ser Val Arg Gly Tyr Cys
          360          365          370

tta tta cat ggt tta gaa tgt ctc gaa gtc att aac cat ata caa aat 1806
Leu Leu His Gly Leu Glu Cys Leu Glu Val Ile Asn His Ile Gln Asn
375          380          385          390

aat agc ctt gag caa agt ttt tat cct aaa act atc agc tac tcc acc 1854
Asn Ser Leu Glu Gln Ser Phe Tyr Pro Lys Thr Ile Ser Tyr Ser Thr
          395          400          405

gta ttc gat cgc cag aca aat aaa aca agg gtt caa gcc ctg aca gaa 1902
Val Phe Asp Arg Gln Thr Asn Lys Thr Arg Val Gln Ala Leu Thr Glu
          410          415          420

gac gat caa atg caa gag cca ttc aag cct gct tta att aat ggg aag 1950
Asp Asp Gln Met Gln Glu Pro Phe Lys Pro Ala Leu Ile Asn Gly Lys
          425          430          435

tac aac aaa ata aaa tca ttg att ggg tat gta caa aga atc gga aac 1998
Tyr Asn Lys Ile Lys Ser Leu Ile Gly Tyr Val Gln Arg Ile Gly Asn
          440          445          450

gca ccc aga gtt gga ggc att aaa gtc aca ttt gca aac gat gca tct 2046
Ala Pro Arg Val Gly Gly Ile Lys Val Thr Phe Ala Asn Asp Ala Ser
455          460          465          470

tat acc ctc ggt aca gta act tca gaa gta aac tca att gaa ctg aat 2094
Tyr Thr Leu Gly Thr Val Thr Ser Glu Val Asn Ser Ile Glu Leu Asn
          475          480          485

gac agc gtt ata acc agc ctg gaa gta tgg gga aat ggc gct att gat 2142
Asp Ser Val Ile Thr Ser Leu Glu Val Trp Gly Asn Gly Ala Ile Asp
          490          495          500

gag gca ttc ttt aca tta agt gac gga cgt caa ttt agg ctt ggc caa 2190
Glu Ala Phe Thr Leu Ser Asp Gly Arg Gln Phe Arg Leu Gly Gln
          505          510          515

cgc tat gcc agt aac tat aga aaa tat gct gtc gat aac cac tat att 2238
Arg Tyr Ala Ser Asn Tyr Arg Lys Tyr Ala Val Asp Asn His Tyr Ile
          520          525          530

tca gga ttg tac tta gcc agt gat gaa cct tca ttg gca ggt caa gca 2286
Ser Gly Leu Tyr Leu Ala Ser Asp Glu Pro Ser Leu Ala Gly Gln Ala
535          540          545          550

```

```
<210> 3
<211> 429
<212> PRT
<213> Xenorhabdus nematophilus
```

<400> 3
 Met Asn Asn Glu Pro Met Asn Thr Asn Glu Ser Gln Ala Ser Glu Ile
 1 5 10 15
 Val Pro Ser Met Asn Glu Ser Ile Leu Ala Ala Pro Tyr Ser Ile Ser
 20 25 30
 Thr Pro Asn Tyr Glu Trp Asp Met Ser Ser Ile Ile Lys Asp Ala Ile
 35 40 45
 Ile Gly Gly Ile Gly Phe Ile Pro Gly Pro Gly Ser Ala Ile Ser Phe
 50 55 60
 Leu Leu Gly Leu Phe Trp Pro Gln Gln Thr Asp Asn Thr Trp Glu Gln
 65 70 75 80
 Ile Leu Gln Lys Val Glu Gln Met Ile Glu Gln Ala Asn Leu Lys Thr
 85 90 95
 Ile Gln Gly Ile Leu Asn Gly Asp Ile Gln Glu Ile Lys Gly Lys Met
 100 105 110
 Glu His Val Gln Phe Met Leu Glu Ser Ser Pro Gly Thr Gln Glu Ser
 115 120 125
 His Asp Ala Tyr Met Phe Leu Ala Arg Tyr Leu Val Ser Ile Asp Glu
 130 135 140
 Lys Phe Lys Ser Phe Asp Asn Lys Thr Asn Tyr Gln Ile Leu Pro Met
 145 150 155 160
 Tyr Thr Asn Thr Ile Met Leu Gln Ala Pro Tyr Trp Lys Met Gly Ile
 165 170 175
 Glu Arg Lys Asp Glu Ile Lys Leu Thr Asp Ile Glu Val Asn Glu Leu
 180 185 190
 Lys Glu Leu Ile Gly Lys Leu Ser Thr Ser Ala Asp Lys Tyr Ile His
 195 200 205
 Asp Val Tyr Thr Arg Glu Tyr Asp Asn Ala Met Asn Thr Ser Thr Ala
 210 215 220
 Ala Asn Ile Thr Asn Asn Leu Leu Ser Val Arg Gly Tyr Cys Leu Leu
 225 230 235 240
 His Gly Leu Glu Cys Leu Glu Val Ile Asn His Ile Gln Asn Asn Ser
 245 250 255
 Leu Glu Gln Ser Phe Tyr Pro Lys Thr Ile Ser Tyr Ser Thr Val Phe
 260 265 270
 Asp Arg Gln Thr Asn Lys Thr Arg Val Gln Ala Leu Thr Glu Asp Asp
 275 280 285
 Gln Met Gln Glu Pro Phe Lys Pro Ala Leu Ile Asn Gly Lys Tyr Asn
 290 295 300
 Lys Ile Lys Ser Leu Ile Gly Tyr Val Gln Arg Ile Gly Asn Ala Pro
 305 310 315 320
 Arg Val Gly Gly Ile Lys Val Thr Phe Ala Asn Asp Ala Ser Tyr Thr
 325 330 335

Leu Gly Thr Val Thr Ser Glu Val Asn Ser Ile Glu Leu Asn Asp Ser
 340 345 350
 Val Ile Thr Ser Leu Glu Val Trp Gly Asn Gly Ala Ile Asp Glu Ala
 355 360 365
 Phe Phe Thr Leu Ser Asp Gly Arg Gln Phe Arg Leu Gly Gln Arg Tyr
 370 375 380
 Ala Ser Asn Tyr Arg Lys Tyr Ala Val Asp Asn His Tyr Ile Ser Gly
 385 390 395 400
 Leu Tyr Leu Ala Ser Asp Glu Pro Ser Leu Ala Gly Gln Ala Ala Gly
 405 410 415
 Ile Ala Val Ser Tyr His Met Ile Ala Asp Lys Lys Ser
 420 425

<210> 4
 <211> 408
 <212> DNA
 <213> Xenorhabdus nematophilus

<220>
 <221> CDS
 <222> (1)..(405)
 <223> orf1 of pCIB9381

<400> 4
 atg att aca atc aat atc act ggt gat aat gta aga gtt aat aac aat 48
 Met Ile Thr Ile Asn Ile Thr Gly Asp Asn Val Arg Val Asn Asn Asn
 1 5 10 15
 ata gca aca gaa acc gac ctc caa aat aca cct gct tca gca ccc tta 96
 Ile Ala Thr Glu Thr Asp Leu Gln Asn Thr Pro Ala Ser Ala Pro Leu
 20 25 30
 tca att att aat ttt agg gat atg aca ata gaa cct cat tca tct gtt 144
 Ser Ile Ile Asn Phe Arg Asp Met Thr Ile Glu Pro His Ser Ser Val
 35 40 45
 gag gcg ata aga acc gat aca ccg att att cct gaa tca cga cca aat 192
 Glu Ala Ile Arg Thr Asp Thr Pro Ile Ile Pro Glu Ser Arg Pro Asn
 50 55 60
 tac tat gtt gct aat tct ggc ccg gcc tca tca gtc aga gct gtt ttc 240
 Tyr Tyr Val Ala Asn Ser Gly Pro Ala Ser Ser Val Arg Ala Val Phe
 65 70 75 80
 tat tgg tcc cac tct ttt aca tca gaa tgg ttt gaa tct tcc tct att 288
 Tyr Trp Ser His Ser Phe Thr Ser Glu Trp Phe Glu Ser Ser Ser Ile
 85 90 95
 att gta aaa gca ggc gaa gac gga gtc tta cat tca ccg ggt aat tct 336
 Ile Val Lys Ala Gly Glu Asp Gly Val Leu His Ser Pro Gly Asn Ser
 100 105 110
 tta tat tac agc aag gtt gta att tat aac gat aca gac aaa cgt gct 384
 Leu Tyr Tyr Ser Lys Val Val Ile Tyr Asn Asp Thr Asp Lys Arg Ala
 115 120 125
 ttt gtt acc ggc tac aat cta taa 408
 Phe Val Thr Gly Tyr Asn Leu
 130 135

<210> 5
 <211> 135
 <212> PRT
 <213> Xenorhabdus nematophilus

<400> 5
 Met Ile Thr Ile Asn Ile Thr Gly Asp Asn Val Arg Val Asn Asn Asn
 1 5 10 15
 Ile Ala Thr Glu Thr Asp Leu Gln Asn Thr Pro Ala Ser Ala Pro Leu
 20 25 30
 Ser Ile Ile Asn Phe Arg Asp Met Thr Ile Glu Pro His Ser Ser Val
 35 40 45
 Glu Ala Ile Arg Thr Asp Thr Pro Ile Ile Pro Glu Ser Arg Pro Asn
 50 55 60
 Tyr Tyr Val Ala Asn Ser Gly Pro Ala Ser Ser Val Arg Ala Val Phe
 65 70 75 80
 Tyr Trp Ser His Ser Phe Thr Ser Glu Trp Phe Glu Ser Ser Ser Ile
 85 90 95
 Ile Val Lys Ala Gly Glu Asp Gly Val Leu His Ser Pro Gly Asn Ser
 100 105 110
 Leu Tyr Tyr Ser Lys Val Val Ile Tyr Asn Asp Thr Asp Lys Arg Ala
 115 120 125
 Phe Val Thr Gly Tyr Asn Leu
 130 135

<210> 6
 <211> 1290
 <212> DNA
 <213> Xenorhabdus nematophilus

<220>
 <221> CDS
 <222> (1)..(1287)
 <223> JHE-like orf2 of pCIB9381

<400> 6
 atg aat aat gaa ccg atg aat act aat gaa tca caa gtt tca gag ata 48
 Met Asn Asn Glu Pro Met Asn Thr Asn Glu Ser Gln Val Ser Glu Ile
 1 5 10 15
 gta ccc tca atg aat gaa tct ata tta gca gca cct tat tca att tct 96
 Val Pro Ser Met Asn Glu Ser Ile Leu Ala Ala Pro Tyr Ser Ile Ser
 20 25 30
 aca cct aat tat gaa tgg gat atg tca tca ata ata aaa gat gcc att 144
 Thr Pro Asn Tyr Glu Trp Asp Met Ser Ser Ile Ile Lys Asp Ala Ile
 35 40 45
 att ggc ggt ata ggc ttt att cct ggt ccg ggc tca gca ata tca ttt 192
 Ile Gly Gly Ile Gly Phe Ile Pro Gly Pro Gly Ser Ala Ile Ser Phe
 50 55 60
 ttg tta ggg tta ttt tgg cca caa caa acc gac aat act tgg gag caa 240
 Leu Leu Gly Leu Phe Trp Pro Gln Gln Thr Asp Asn Thr Trp Glu Gln

65	70	75	80	
att ctc caa aaa gta gaa caa atg atc gag caa gcc aat ctc aaa act				288
Ile Leu Gln Lys Val Glu Gln Met Ile Glu Gln Ala Asn Leu Lys Thr	85	90	95	
att caa gga ata ttg aac ggc gat ata caa gaa att aaa ggc aaa atg				336
Ile Gln Gly Ile Leu Asn Gly Asp Ile Gln Glu Ile Lys Gly Lys Met	100	105	110	
gaa cat gtg caa ttc atg cta gaa tcc tca cct ggc act caa gaa agc				384
Glu His Val Gln Phe Met Leu Glu Ser Ser Pro Gly Thr Gln Glu Ser	115	120	125	
cat gac gca tac atg ttt ctg gcg aga tat ctg gtc agt ata gac gaa				432
His Asp Ala Tyr Met Phe Leu Ala Arg Tyr Leu Val Ser Ile Asp Glu	130	135	140	
aaa ttc aag tct ttt gat aac aaa aca aat tat caa att ctt ccc atg				480
Lys Phe Lys Ser Phe Asp Asn Lys Thr Asn Tyr Gln Ile Leu Pro Met	145	150	155	160
tat acc aat acg att atg tta caa gcc cct tat tgg aaa atg ggt ata				528
Tyr Thr Asn Thr Ile Met Leu Gln Ala Pro Tyr Trp Lys Met Gly Ile	165	170	175	
gag aga aaa gat gag ata aaa cta aca gat ata gaa gtt aat gaa tta				576
Glu Arg Lys Asp Glu Ile Lys Leu Thr Asp Ile Glu Val Asn Glu Leu	180	185	190	
aaa gag ctg ata gga aaa tta tct acc agc gcc gat aaa tat att cat				624
Lys Glu Leu Ile Gly Lys Leu Ser Thr Ser Ala Asp Lys Tyr Ile His	195	200	205	
gat gtc tat act cgt gaa tat gat aat gcg atg aac act tca aca gca				672
Asp Val Tyr Thr Arg Glu Tyr Asp Asn Ala Met Asn Thr Ser Thr Ala	210	215	220	
gca aat atc acc aat aat tta tta tct gta aga ggc tat tgt tta tta				720
Ala Asn Ile Thr Asn Asn Leu Leu Ser Val Arg Gly Tyr Cys Leu Leu	225	230	235	240
cat ggt tta gaa tgt ctc gaa gtc att aac cat ata caa aat aat agc				768
His Gly Leu Glu Cys Leu Glu Val Ile Asn His Ile Gln Asn Asn Ser	245	250	255	
ctt gag caa agt ttt tat cct aaa act atc agc tac tcc acc gta ttc				816
Leu Glu Gln Ser Phe Tyr Pro Lys Thr Ile Ser Tyr Ser Thr Val Phe	260	265	270	
gat cgc cag aca aat aaa aca agg gtt caa gcc ctg aca gaa gac gat				864
Asp Arg Gln Thr Asn Lys Thr Arg Val Gln Ala Leu Thr Glu Asp Asp	275	280	285	
caa atg caa gag cca ttc aag cct gct tta att aat ggg aag tac aac				912
Gln Met Gln Glu Pro Phe Lys Pro Ala Leu Ile Asn Gly Lys Tyr Asn	290	295	300	
aaa ata aaa tca ttg att ggg tat gta caa aga atc gga aac gca ccc				960
Lys Ile Lys Ser Leu Ile Gly Tyr Val Gln Arg Ile Gly Asn Ala Pro	305	310	315	320
aga gtt gga ggc att aaa gtc aca ttt gca aac gat gca tct tat acc				1008
Arg Val Gly Gly Ile Lys Val Thr Phe Ala Asn Asp Ala Ser Tyr Thr	325	330	335	

```

ctc ggt aca gta act tca gaa gta aac tca att gaa ctg aat gac agc 1056
Leu Gly Thr Val Thr Ser Glu Val Asn Ser Ile Glu Leu Asn Asp Ser
      340      345      350

gtt ata acc agc ctg gaa gta tgg gga aat ggc gct gtt gat gag gca 1104
Val Ile Thr Ser Leu Glu Val Trp Gly Asn Gly Ala Val Asp Glu Ala
      355      360      365

ttc ttt aca tta agt gac gga cgt caa ttt agg ctt ggc caa cgc tat 1152
Phe Phe Thr Leu Ser Asp Gly Arg Gln Phe Arg Leu Gly Gln Arg Tyr
      370      375      380

gcc agt aac tat aga aaa tat gct gtc gat aac cac tat att tca gga 1200
Ala Ser Asn Tyr Arg Lys Tyr Ala Val Asp Asn His Tyr Ile Ser Gly
      385      390      395      400

ttg tac tta gcc agt gat gaa cct tca ttg gca ggt caa gca gca ggc 1248
Leu Tyr Leu Ala Ser Asp Glu Pro Ser Leu Ala Gly Gln Ala Ala Gly
      405      410      415

att gca gtt tca tac cat atg ata gct gat aaa aaa tca tag 1290
Ile Ala Val Ser Tyr His Met Ile Ala Asp Lys Lys Ser
      420      425

```

<210> 7

<211> 429

<212> PRT

<213> Xenorhabdus nematophilus

<400> 7

```

Met Asn Asn Glu Pro Met Asn Thr Asn Glu Ser Gln Val Ser Glu Ile
  1           5           10          15

Val Pro Ser Met Asn Glu Ser Ile Leu Ala Ala Pro Tyr Ser Ile Ser
      20      25      30

Thr Pro Asn Tyr Glu Trp Asp Met Ser Ser Ile Ile Lys Asp Ala Ile
      35      40      45

Ile Gly Gly Ile Gly Phe Ile Pro Gly Pro Gly Ser Ala Ile Ser Phe
      50      55      60

Leu Leu Gly Leu Phe Trp Pro Gln Gln Thr Asp Asn Thr Trp Glu Gln
      65      70      75      80

Ile Leu Gln Lys Val Glu Gln Met Ile Glu Gln Ala Asn Leu Lys Thr
      85      90      95

Ile Gln Gly Ile Leu Asn Gly Asp Ile Gln Glu Ile Lys Gly Lys Met
      100      105      110

Glu His Val Gln Phe Met Leu Glu Ser Ser Pro Gly Thr Gln Glu Ser
      115      120      125

His Asp Ala Tyr Met Phe Leu Ala Arg Tyr Leu Val Ser Ile Asp Glu
      130      135      140

Lys Phe Lys Ser Phe Asp Asn Lys Thr Asn Tyr Gln Ile Leu Pro Met
      145      150      155      160

Tyr Thr Asn Thr Ile Met Leu Gln Ala Pro Tyr Trp Lys Met Gly Ile
      165      170      175

```

Glu Arg Lys Asp Glu Ile Lys Leu Thr Asp Ile Glu Val Asn Glu Leu
 180 185 190
 Lys Glu Leu Ile Gly Lys Leu Ser Thr Ser Ala Asp Lys Tyr Ile His
 195 200 205
 Asp Val Tyr Thr Arg Glu Tyr Asp Asn Ala Met Asn Thr Ser Thr Ala
 210 215 220
 Ala Asn Ile Thr Asn Asn Leu Leu Ser Val Arg Gly Tyr Cys Leu Leu
 225 230 235 240
 His Gly Leu Glu Cys Leu Glu Val Ile Asn His Ile Gln Asn Asn Ser
 245 250 255
 Leu Glu Gln Ser Phe Tyr Pro Lys Thr Ile Ser Tyr Ser Thr Val Phe
 260 265 270
 Asp Arg Gln Thr Asn Lys Thr Arg Val Gln Ala Leu Thr Glu Asp Asp
 275 280 285
 Gln Met Gln Glu Pro Phe Lys Pro Ala Leu Ile Asn Gly Lys Tyr Asn
 290 295 300
 Lys Ile Lys Ser Leu Ile Gly Tyr Val Gln Arg Ile Gly Asn Ala Pro
 305 310 315 320
 Arg Val Gly Gly Ile Lys Val Thr Phe Ala Asn Asp Ala Ser Tyr Thr
 325 330 335
 Leu Gly Thr Val Thr Ser Glu Val Asn Ser Ile Glu Leu Asn Asp Ser
 340 345 350
 Val Ile Thr Ser Leu Glu Val Trp Gly Asn Gly Ala Val Asp Glu Ala
 355 360 365
 Phe Phe Thr Leu Ser Asp Gly Arg Gln Phe Arg Leu Gly Gln Arg Tyr
 370 375 380
 Ala Ser Asn Tyr Arg Lys Tyr Ala Val Asp Asn His Tyr Ile Ser Gly
 385 390 395 400
 Leu Tyr Leu Ala Ser Asp Glu Pro Ser Leu Ala Gly Gln Ala Ala Gly
 405 410 415
 Ile Ala Val Ser Tyr His Met Ile Ala Asp Lys Lys Ser
 420 425

<210> 8
 <211> 408
 <212> DNA
 <213> Xenorhabdus poinarii

<220>
 <221> CDS
 <222> (1)..(405)
 <223> orf1 of pCIB9354

<400> 8
 atg atc aca atc aat atc agt ggt ggt aat gta aca att aat aac aat 48
 Met Ile Thr Ile Asn Ile Ser Gly Gly Asn Val Thr Ile Asn Asn Asn
 1 5 10 15
 atc agt tca gta acg gat atc caa aaa ccc ctt gat gca gaa ccc ctc 96

```

Ile Ser Ser Val Thr Asp Ile Gln Lys Pro Leu Asp Ala Glu Pro Leu
    20          25          30
tca gtc acg aat tat aga gat ctg aca ata gag ccg cac tca tct att 144
Ser Val Thr Asn Tyr Arg Asp Leu Thr Ile Glu Pro His Ser Ser Ile
    35          40          45
caa gca gac aga acg gac acc ccc att att cct gaa aca cgc cct gat 192
Gln Ala Asp Arg Thr Asp Thr Pro Ile Ile Pro Glu Thr Arg Pro Asp
    50          55          60
tat tat atc gct aac tca ggc cct gct tca tca gtc aaa gct gtg ttt 240
Tyr Tyr Ile Ala Asn Ser Gly Pro Ala Ser Ser Val Lys Ala Val Phe
    65          70          75          80
tat tgg tcg cat tcg ttt aca tcg gaa tgg ttc gag tat tca tct atc 288
Tyr Trp Ser His Ser Phe Thr Ser Glu Trp Phe Glu Tyr Ser Ser Ile
    85          90          95
acg gta aaa gca gga gaa gat gga ata tta aaa tca ccg agt aat gct 336
Thr Val Lys Ala Gly Glu Asp Gly Ile Leu Lys Ser Pro Ser Asn Ala
    100          105          110
gta tat tac agt aaa gta gtc att tat aat gat aca gat aag cgg gct 384
Val Tyr Tyr Ser Lys Val Val Ile Tyr Asn Asp Thr Asp Lys Arg Ala
    115          120          125
ttt gtg act gga tat aac atg taa 408
Phe Val Thr Gly Tyr Asn Met
    130          135

```

<210> 9
 <211> 135
 <212> PRT
 <213> Xenorhabdus poinarii

```

<400> 9
Met Ile Thr Ile Asn Ile Ser Gly Gly Asn Val Thr Ile Asn Asn Asn
    1          5          10          15
Ile Ser Ser Val Thr Asp Ile Gln Lys Pro Leu Asp Ala Glu Pro Leu
    20          25          30
Ser Val Thr Asn Tyr Arg Asp Leu Thr Ile Glu Pro His Ser Ser Ile
    35          40          45
Gln Ala Asp Arg Thr Asp Thr Pro Ile Ile Pro Glu Thr Arg Pro Asp
    50          55          60
Tyr Tyr Ile Ala Asn Ser Gly Pro Ala Ser Ser Val Lys Ala Val Phe
    65          70          75          80
Tyr Trp Ser His Ser Phe Thr Ser Glu Trp Phe Glu Tyr Ser Ser Ile
    85          90          95
Thr Val Lys Ala Gly Glu Asp Gly Ile Leu Lys Ser Pro Ser Asn Ala
    100          105          110
Val Tyr Tyr Ser Lys Val Val Ile Tyr Asn Asp Thr Asp Lys Arg Ala
    115          120          125
Phe Val Thr Gly Tyr Asn Met
    130          135

```

<210> 10
 <211> 1056
 <212> DNA
 <213> Xenorhabdus poinarii

<220>
 <221> CDS
 <222> (1)..(1053)
 <223> JHE-like orf2 of pCIB9354

<400> 10
 atg aat aat agt cca atg aat gat cag tta tca aca gcg cct tat tca 48
 Met Asn Asn Ser Pro Met Asn Asp Gln Leu Ser Thr Ala Pro Tyr Ser
 1 5 10 15
 att tcg aca ccc aat tat gaa tgg gat atg tca tca atc ata aaa gat 96
 Ile Ser Thr Pro Asn Tyr Glu Trp Asp Met Ser Ser Ile Ile Lys Asp
 20 25 30
 gcc att atc ggt ggc ata gga ttt att ccc gga cca ggc cct gca atc 144
 Ala Ile Ile Gly Gly Ile Gly Phe Ile Pro Gly Pro Gly Pro Ala Ile
 35 40 45
 tct ttt tta tta gga ctg ttc tgg cca caa cag aca gac aat acc tgg 192
 Ser Phe Leu Leu Gly Leu Phe Trp Pro Gln Gln Thr Asp Asn Thr Trp
 50 55 60
 gat caa atc ctc caa aaa atc gaa caa atg ata gaa gaa gcg aat tta 240
 Asp Gln Ile Leu Gln Lys Ile Glu Gln Met Ile Glu Glu Ala Asn Leu
 65 70 75 80
 aaa acc att aaa ggt ata tta aat gga gat ata caa gaa att aaa gga 288
 Lys Thr Ile Lys Gly Ile Leu Asn Gly Asp Ile Gln Glu Ile Lys Gly
 85 90 95
 aaa atg gac cat gtg aaa tct atg cta gag aat tct cct ggc agc cag 336
 Lys Met Asp His Val Lys Ser Met Leu Glu Asn Ser Pro Gly Ser Gln
 100 105 110
 gaa agc cat gat gct tat atg ttt ctg gca agg ttt ttg gtc agt att 384
 Glu Ser His Asp Ala Tyr Met Phe Leu Ala Arg Phe Leu Val Ser Ile
 115 120 125
 gat gaa aaa ttc aaa tct ttc gat gat aga aca aat tat caa att ctt 432
 Asp Glu Lys Phe Lys Ser Phe Asp Asp Arg Thr Asn Tyr Gln Ile Leu
 130 135 140
 ccc atg tac acg aat aca att atg tta caa gcg cct tat tgg aaa atg 480
 Pro Met Tyr Thr Asn Thr Ile Met Leu Gln Ala Pro Tyr Trp Lys Met
 145 150 155 160
 ggc atc gaa aag aaa gag gat atc ggt tta acc gat att gaa gtt ggt 528
 Gly Ile Glu Lys Lys Glu Asp Ile Gly Leu Thr Asp Ile Glu Val Gly
 165 170 175
 gaa tta aaa gaa ctt atc gat aaa tta tat act aaa tca tat gat tat 576
 Glu Leu Lys Glu Leu Ile Asp Lys Tyr Thr Lys Ser Tyr Asp Tyr
 180 185 190
 atc aat aat acg tat aat cgt gaa tat aat aat gca atc aat acg tca 624
 Ile Asn Asn Thr Tyr Asn Arg Glu Tyr Asn Asn Ala Ile Asn Thr Ser
 195 200 205
 acc gca gag agt atc acc aat aat tta ttg tct gtc aga gga tat tgt 672

```

Thr Ala Glu Ser Ile Thr Asn Asn Leu Leu Ser Val Arg Gly Tyr Cys
210                215                220

tta tta cat ggt tgt gaa tgc ctt gaa gtt att gcg cat ata caa aac 720
Leu Leu His Gly Cys Glu Cys Leu Glu Val Ile Ala His Ile Gln Asn
225                230                235                240

aat agt ctt gat aaa ggc ttc tac cct aaa acg atc agc tat tcg agt 768
Asn Ser Leu Asp Lys Gly Phe Tyr Pro Lys Thr Ile Ser Tyr Ser Ser
245                250                255

gtt ttc gat cgt cct aca aac aaa atg aga att cag gcg ctt aca gaa 816
Val Phe Asp Arg Pro Thr Asn Lys Met Arg Ile Gln Ala Leu Thr Glu
260                265                270

gat gac caa atg caa gaa ccg ttc aaa cct tct ttc gtc aat ggt caa 864
Asp Asp Gln Met Gln Glu Pro Phe Lys Pro Ser Phe Val Asn Gly Gln
275                280                285

tat aat aaa ata aaa tca ttg gag ggt tat gtc aca agg atc ggc aat 912
Tyr Asn Lys Ile Lys Ser Leu Glu Gly Tyr Val Thr Arg Ile Gly Asn
290                295                300

gcc ccc cga gtc ggc gga att aaa atc aca ttt gaa aac aac gca tct 960
Ala Pro Arg Val Gly Gly Ile Lys Ile Thr Phe Glu Asn Asn Ala Ser
305                310                315                320

tat act ctt ggc act gta act tca gaa aca acc tct att gaa ctc aat 1008
Tyr Thr Leu Gly Thr Val Thr Ser Glu Thr Thr Ser Ile Glu Leu Asn
325                330                335

gag agt gtt ata acc agc ata gaa gtg tgg gga gag tgg tgc cgt tga 1056
Glu Ser Val Ile Thr Ser Ile Glu Val Trp Gly Glu Trp Cys Arg
340                345                350

```

<210> 11
 <211> 351
 <212> PRT
 <213> Xenorhabdus poinarii

```

<400> 11
Met Asn Asn Ser Pro Met Asn Asp Gln Leu Ser Thr Ala Pro Tyr Ser
1                5                10                15

Ile Ser Thr Pro Asn Tyr Glu Trp Asp Met Ser Ser Ile Ile Lys Asp
20                25                30

Ala Ile Ile Gly Gly Ile Gly Phe Ile Pro Gly Pro Gly Pro Ala Ile
35                40                45

Ser Phe Leu Leu Gly Leu Phe Trp Pro Gln Gln Thr Asp Asn Thr Trp
50                55                60

Asp Gln Ile Leu Gln Lys Ile Glu Gln Met Ile Glu Glu Ala Asn Leu
65                70                75                80

Lys Thr Ile Lys Gly Ile Leu Asn Gly Asp Ile Gln Glu Ile Lys Gly
85                90                95

Lys Met Asp His Val Lys Ser Met Leu Glu Asn Ser Pro Gly Ser Gln
100               105               110

Glu Ser His Asp Ala Tyr Met Phe Leu Ala Arg Phe Leu Val Ser Ile
115               120               125

```

Asp Glu Lys Phe Lys Ser Phe Asp Asp Arg Thr Asn Tyr Gln Ile Leu
 130 135 140
 Pro Met Tyr Thr Asn Thr Ile Met Leu Gln Ala Pro Tyr Trp Lys Met
 145 150 155 160
 Gly Ile Glu Lys Lys Glu Asp Ile Gly Leu Thr Asp Ile Glu Val Gly
 165 170 175
 Glu Leu Lys Glu Leu Ile Asp Lys Leu Tyr Thr Lys Ser Tyr Asp Tyr
 180 185 190
 Ile Asn Asn Thr Tyr Asn Arg Glu Tyr Asn Asn Ala Ile Asn Thr Ser
 195 200 205
 Thr Ala Glu Ser Ile Thr Asn Asn Leu Leu Ser Val Arg Gly Tyr Cys
 210 215 220
 Leu Leu His Gly Cys Glu Cys Leu Glu Val Ile Ala His Ile Gln Asn
 225 230 235 240
 Asn Ser Leu Asp Lys Gly Phe Tyr Pro Lys Thr Ile Ser Tyr Ser Ser
 245 250 255
 Val Phe Asp Arg Pro Thr Asn Lys Met Arg Ile Gln Ala Leu Thr Glu
 260 265 270
 Asp Asp Gln Met Gln Glu Pro Phe Lys Pro Ser Phe Val Asn Gly Gln
 275 280 285
 Tyr Asn Lys Ile Lys Ser Leu Glu Gly Tyr Val Thr Arg Ile Gly Asn
 290 295 300
 Ala Pro Arg Val Gly Gly Ile Lys Ile Thr Phe Glu Asn Asn Ala Ser
 305 310 315 320
 Tyr Thr Leu Gly Thr Val Thr Ser Glu Thr Thr Ser Ile Glu Leu Asn
 325 330 335
 Glu Ser Val Ile Thr Ser Ile Glu Val Trp Gly Glu Trp Cys Arg
 340 345 350

<210> 12
 <211> 408
 <212> DNA
 <213> Photorhabdus luminescens

<220>
 <221> CDS
 <222> (1)..(405)
 <223> orf1 of pCIB9383-21

<400> 12
 atg att aca atc aat atc act ggt gat aat gta aga gtt aat aac aat 48
 Met Ile Thr Ile Asn Ile Thr Gly Asp Asn Val Arg Val Asn Asn
 1 5 10 15
 ata gca aca gaa acc gac ctc caa aat aca cct gct tca gca ccc tta 96
 Ile Ala Thr Glu Thr Asp Leu Gln Asn Thr Pro Ala Ser Ala Pro Leu
 20 25 30
 tca att att aat ttt agg gat atg aca ata gaa cct cat tca tct gtt 144
 Ser Ile Ile Asn Phe Arg Asp Met Thr Ile Glu Pro His Ser Ser Val

```

          35          40          45
gag gcg ata aga acc gat aca ccg att att cct gaa tca cga cca aat 192
Glu Ala Ile Arg Thr Asp Thr Pro Ile Ile Pro Glu Ser Arg Pro Asn
      50          55          60

tac tat gtt gct aat tct ggc ccg gcc tca tca gtc aga gct gtt ttc 240
Tyr Tyr Val Ala Asn Ser Gly Pro Ala Ser Ser Val Arg Ala Val Phe
      65          70          75          80

tat tgg tcc cac tct ttt aca tca gaa tgg ttt gaa tct tcc tct att 288
Tyr Trp Ser His Ser Phe Thr Ser Glu Trp Phe Glu Ser Ser Ser Ile
          85          90          95

att gta aaa gca ggc gaa gac gga gtc tta cat tca ccg ggt aat tct 336
Ile Val Lys Ala Gly Glu Asp Gly Val Leu His Ser Pro Gly Asn Ser
          100          105          110

tta tat tac agc aag gtt gta att tat aac gat aca gac aaa cgt gct 384
Leu Tyr Tyr Ser Lys Val Val Ile Tyr Asn Asp Thr Asp Lys Arg Ala
          115          120          125

ttt gtt acc ggc tac aat cta taa 408
Phe Val Thr Gly Tyr Asn Leu
      130          135

```

<210> 13
 <211> 135
 <212> PRT
 <213> Photorhabdus luminescens

```

<400> 13
Met Ile Thr Ile Asn Ile Thr Gly Asp Asn Val Arg Val Asn Asn Asn
  1          5          10          15

Ile Ala Thr Glu Thr Asp Leu Gln Asn Thr Pro Ala Ser Ala Pro Leu
      20          25          30

Ser Ile Ile Asn Phe Arg Asp Met Thr Ile Glu Pro His Ser Ser Val
      35          40          45

Glu Ala Ile Arg Thr Asp Thr Pro Ile Ile Pro Glu Ser Arg Pro Asn
      50          55          60

Tyr Tyr Val Ala Asn Ser Gly Pro Ala Ser Ser Val Arg Ala Val Phe
      65          70          75          80

Tyr Trp Ser His Ser Phe Thr Ser Glu Trp Phe Glu Ser Ser Ser Ile
          85          90          95

Ile Val Lys Ala Gly Glu Asp Gly Val Leu His Ser Pro Gly Asn Ser
      100          105          110

Leu Tyr Tyr Ser Lys Val Val Ile Tyr Asn Asp Thr Asp Lys Arg Ala
      115          120          125

Phe Val Thr Gly Tyr Asn Leu
      130          135

```

<210> 14
 <211> 1320
 <212> DNA
 <213> Photorhabdus luminescens


```

<220>
<221> CDS
<222> (1)..(1317)
<223> JHE-like orf2 of pCIB9383-21

<400> 14
atg aat aat gaa ccg atg aat act aat gaa tca caa gct tca gag ata 48
Met Asn Asn Glu Pro Met Asn Thr Asn Glu Ser Gln Ala Ser Glu Ile
1 5 10 15

gta ccc tca atg aat gaa tct ata tta aat gaa tct ata tta aat gaa 96
Val Pro Ser Met Asn Glu Ser Ile Leu Asn Glu Ser Ile Leu Asn Glu
20 25 30

tct ata tta gca gca cct tat tca att tct aca cct aat tat gaa tgg 144
Ser Ile Leu Ala Ala Pro Tyr Ser Ile Ser Thr Pro Asn Tyr Glu Trp
35 40 45

gat atg tca tca ata ata aaa gat gcc att att ggt ggt ata ggc ttt 192
Asp Met Ser Ser Ile Ile Lys Asp Ala Ile Ile Gly Gly Ile Gly Phe
50 55 60

att cct ggt ccg ggc tca gca ata tca ttt ttg tta ggg tta ttt tgg 240
Ile Pro Gly Pro Gly Ser Ala Ile Ser Phe Leu Leu Gly Leu Phe Trp
65 70 75 80

cca caa caa acc gac aat act tgg gag caa att ctc caa aaa gta gaa 288
Pro Gln Gln Thr Asp Asn Thr Trp Glu Gln Ile Leu Gln Lys Val Glu
85 90 95

caa atg atc gag caa gcc aat ctc aaa act att caa gga ata ttg aac 336
Gln Met Ile Glu Gln Ala Asn Leu Lys Thr Ile Gln Gly Ile Leu Asn
100 105 110

ggc gat ata caa gaa att aaa ggc aaa atg gaa cat gtg caa ttc atg 384
Gly Asp Ile Gln Glu Ile Lys Gly Lys Met Glu His Val Gln Phe Met
115 120 125

cta gaa tcc tca cct ggc act caa gaa agc cat gac gca tac atg ttt 432
Leu Glu Ser Ser Pro Gly Thr Gln Glu Ser His Asp Ala Tyr Met Phe
130 135 140

ctg gcg aga tat ctg gtc agt ata gac gaa aaa ttc aag tct ttt gat 480
Leu Ala Arg Tyr Leu Val Ser Ile Asp Glu Lys Phe Lys Ser Phe Asp
145 150 155 160

aac aaa aca aat tat caa att ctt ccc atg tat acc aat acg att atg 528
Asn Lys Thr Asn Tyr Gln Ile Leu Pro Met Tyr Thr Asn Thr Ile Met
165 170 175

tta caa gcc cct tat tgg aaa atg ggt ata gag aga aaa gat gag ata 576
Leu Gln Ala Pro Tyr Trp Lys Met Gly Ile Glu Arg Lys Asp Glu Ile
180 185 190

aaa cta aca gat ata gaa gtt aat gaa tta aaa gag ctg ata gga aaa 624
Lys Leu Thr Asp Ile Glu Val Asn Glu Leu Lys Glu Leu Ile Gly Lys
195 200 205

tta tct acc agc gcc gat aaa tat att cat gat gtc tat act cgt gaa 672
Leu Ser Thr Ser Ala Asp Lys Tyr Ile His Asp Val Tyr Thr Arg Glu
210 215 220

tat gat aat gcg atg aac act tca aca gca gca aat atc acc aat aat 720
Tyr Asp Asn Ala Met Asn Thr Ser Thr Ala Ala Asn Ile Thr Asn Asn

```

```

225          230          235          240
tta tta tct gta aga ggc tat tgt tta tta cat ggt tta gaa tgt ctc 768
Leu Leu Ser Val Arg Gly Tyr Cys Leu Leu His Gly Leu Glu Cys Leu
                245                250                255

gaa gtc att aac cat ata caa aat aat agc ctt gag caa agt ttt tat 816
Glu Val Ile Asn His Ile Gln Asn Asn Ser Leu Glu Gln Ser Phe Tyr
                260                265                270

cct aaa act atc agc tac tcc acc gta ttc gat cgc cag aca aat aaa 864
Pro Lys Thr Ile Ser Tyr Ser Thr Val Phe Asp Arg Gln Thr Asn Lys
                275                280                285

aca agg gtt caa gcc ctg aca gaa gac gat caa atg caa gag cca ttc 912
Thr Arg Val Gln Ala Leu Thr Glu Asp Asp Gln Met Gln Glu Pro Phe
                290                295                300

aag cct gct tta att aat ggg aag tac aac aaa ata aaa tca ttg att 960
Lys Pro Ala Leu Ile Asn Gly Lys Tyr Asn Lys Ile Lys Ser Leu Ile
305                310                315                320

ggg tat gta caa aga atc gga aac gca ccc aga gtt gga ggc att aaa 1008
Gly Tyr Val Gln Arg Ile Gly Asn Ala Pro Arg Val Gly Gly Ile Lys
                325                330                335

gtc aca ttt gca aac gat gca tct tat acc ctc ggt aca gta act tca 1056
Val Thr Phe Ala Asn Asp Ala Ser Tyr Thr Leu Gly Thr Val Thr Ser
                340                345                350

gaa gta aac tca att gaa ctg aat gac agc gtt ata acc agc ctg gaa 1104
Glu Val Asn Ser Ile Glu Leu Asn Asp Ser Val Ile Thr Ser Leu Glu
                355                360                365

gta tgg gga aat ggc gct gtt gat gag gca ttc ttt aca tta agt gac 1152
Val Trp Gly Asn Gly Ala Val Asp Glu Ala Phe Phe Thr Leu Ser Asp
370                375                380

gga cgt caa ttt agg ctt ggc caa cgc tat gcc agt aac tat aga aaa 1200
Gly Arg Gln Phe Arg Leu Gly Gln Arg Tyr Ala Ser Asn Tyr Arg Lys
385                390                395                400

tat gct gtc gat aac cac tat att tca gga ttg tac tta gcc agt gat 1248
Tyr Ala Val Asp Asn His Tyr Ile Ser Gly Leu Tyr Leu Ala Ser Asp
                405                410                415

gaa.cct tca ttg gca ggt caa gca gca ggc att gca gtt tca tac cat 1296
Glu Pro Ser Leu Ala Gly Gln Ala Ala Gly ile Ala Val Ser Tyr His
                420                425                430

atg ata gct gat aaa aaa tca tag 1320
Met Ile Ala Asp Lys Lys Ser
                435

```

<210> 15

<211> 439

<212> PRT

<213> Photorhabdus luminescens

<400> 15

```

Met Asn Asn Glu Pro Met Asn Thr Asn Glu Ser Gln Ala Ser Glu Ile
  1              5              10              15

```

```

Val Pro Ser Met Asn Glu Ser Ile Leu Asn Glu Ser Ile Leu Asn Glu

```

20										25										30													
Ser	Ile	Leu	Ala	Ala	Pro	Tyr	Ser	Ile	Ser	Thr	Pro	Asn	Tyr	Glu	Trp																		
		35						40				45																					
Asp	Met	Ser	Ser	Ile	Ile	Lys	Asp	Ala	Ile	Ile	Gly	Gly	Ile	Gly	Phe																		
	50					55					60																						
Ile	Pro	Gly	Pro	Gly	Ser	Ala	Ile	Ser	Phe	Leu	Leu	Gly	Leu	Phe	Trp																		
	65				70					75					80																		
Pro	Gln	Gln	Thr	Asp	Asn	Thr	Trp	Glu	Gln	Ile	Leu	Gln	Lys	Val	Glu																		
				85					90					95																			
Gln	Met	Ile	Glu	Gln	Ala	Asn	Leu	Lys	Thr	Ile	Gln	Gly	Ile	Leu	Asn																		
		100					105						110																				
Gly	Asp	Ile	Gln	Glu	Ile	Lys	Gly	Lys	Met	Glu	His	Val	Gln	Phe	Met																		
		115					120					125																					
Leu	Glu	Ser	Ser	Pro	Gly	Thr	Gln	Glu	Ser	His	Asp	Ala	Tyr	Met	Phe																		
	130					135					140																						
Leu	Ala	Arg	Tyr	Leu	Val	Ser	Ile	Asp	Glu	Lys	Phe	Lys	Ser	Phe	Asp																		
	145				150				155						160																		
Asn	Lys	Thr	Asn	Tyr	Gln	Ile	Leu	Pro	Met	Tyr	Thr	Asn	Thr	Ile	Met																		
				165					170					175																			
Leu	Gln	Ala	Pro	Tyr	Trp	Lys	Met	Gly	Ile	Glu	Arg	Lys	Asp	Glu	Ile																		
		180						185					190																				
Lys	Leu	Thr	Asp	Ile	Glu	Val	Asn	Glu	Leu	Lys	Glu	Leu	Ile	Gly	Lys																		
	195					200						205																					
Leu	Ser	Thr	Ser	Ala	Asp	Lys	Tyr	Ile	His	Asp	Val	Tyr	Thr	Arg	Glu																		
	210				215					220																							
Tyr	Asp	Asn	Ala	Met	Asn	Thr	Ser	Thr	Ala	Ala	Asn	Ile	Thr	Asn	Asn																		
	225				230				235					240																			
Leu	Leu	Ser	Val	Arg	Gly	Tyr	Cys	Leu	Leu	His	Gly	Leu	Glu	Cys	Leu																		
			245					250					255																				
Glu	Val	Ile	Asn	His	Ile	Gln	Asn	Asn	Ser	Leu	Glu	Gln	Ser	Phe	Tyr																		
		260				265						270																					
Pro	Lys	Thr	Ile	Ser	Tyr	Ser	Thr	Val	Phe	Asp	Arg	Gln	Thr	Asn	Lys																		
		275				280						285																					
Thr	Arg	Val	Gln	Ala	Leu	Thr	Glu	Asp	Asp	Gln	Met	Gln	Glu	Pro	Phe																		
	290				295					300																							
Lys	Pro	Ala	Leu	Ile	Asn	Gly	Lys	Tyr	Asn	Lys	Ile	Lys	Ser	Leu	Ile																		
	305				310				315					320																			
Gly	Tyr	Val	Gln	Arg	Ile	Gly	Asn	Ala	Pro	Arg	Val	Gly	Gly	Ile	Lys																		
			325					330					335																				
Val	Thr	Phe	Ala	Asn	Asp	Ala	Ser	Tyr	Thr	Leu	Gly	Thr	Val	Thr	Ser																		
		340				345						350																					
Glu	Val	Asn	Ser	Ile	Glu	Leu	Asn	Asp	Ser	Val	Ile	Thr	Ser	Leu	Glu																		
		355				360						365																					

Val Trp Gly Asn Gly Ala Val Asp Glu Ala Phe Phe Thr Leu Ser Asp
370 375 380

Gly Arg Gln Phe Arg Leu Gly Gln Arg Tyr Ala Ser Asn Tyr Arg Lys
385 390 395 400

Tyr Ala Val Asp Asn His Tyr Ile Ser Gly Leu Tyr Leu Ala Ser Asp
405 410 415

Glu Pro Ser Leu Ala Gly Gln Ala Ala Gly Ile Ala Val Ser Tyr His
420 425 430

Met Ile Ala Asp Lys Lys Ser
435

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/02629

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/31 C07K14/24 C12N1/21 C12N1/19 C12N5/10
A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 00647 A (COMMW SCIENT IND RES ORG ;SMIGIELSKI ADAM JOSEPH (AU); AKHURST RAY) 5 January 1995 (1995-01-05) cited in the application the whole document ---	
A	WO 93 03154 A (MYCOGEN CORP ;KUBOTA KK (JP)) 18 February 1993 (1993-02-18) SEQ ID NO:2 ---	
A	WO 96 38547 A (UNIV CALIFORNIA) 5 December 1996 (1996-12-05) the whole document ---	
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 September 1999

Date of mailing of the international search report

13/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Billang, J

INTERNATIONAL SEARCH REPORT

Internati Application No
PCT/EP 99/02629

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DAVID JOSEPH BOWEN: "Characterization of a High Molecular Weight Insecticidal Protein Complex Produced by the Entomopathogenic Bacterium Photorhabdus luminescens (Nematodes, Biological Control)", THESIS UNIVERSITY WISCONSIN XP002076022 page 52 - page 58 page 63 - page 128 ----	
A	STEMMER W P C: "RAPID EVOLUTION OF A PROTEIN IN VITRO BY DNA SHUFFLING" NATURE, vol. 370, 4 August 1994 (1994-08-04), pages 389-391, XP002912216 ISSN: 0028-0836 cited in the application the whole document ----	34
P, A	BOWEN D ET AL.: "INSECTICIDAL TOXINS FROM THE BACTERIUM Photorhabdus luminescens" SCIENCE, vol. 280, 26 June 1998 (1998-06-26), pages 2129-2132, XP002115650 the whole document -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/02629

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02629

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9500647 A	05-01-1995	AU 675335 B	30-01-1997
		AU 6991694 A	17-01-1995
		EP 0705340 A	10-04-1996
		JP 9500264 T	14-01-1997
WO 9303154 A	18-02-1993	AT 174626 T	15-01-1999
		AU 675628 B	13-02-1997
		AU 2411692 A	02-03-1993
		CA 2112676 A	18-02-1993
		DE 69227911 D	28-01-1999
		DE 69227911 T	12-05-1999
		EP 0602064 A	22-06-1994
		ES 2124738 T	16-02-1999
		JP 2842578 B	06-01-1999
		JP 7000179 A	06-01-1995
		US 5747450 A	05-05-1998
		US 5824878 A	20-10-1998
		US 5359048 A	25-10-1994
		ZA 9205447 A	18-05-1993
WO 9638547 A	05-12-1996	US 5674485 A	07-10-1997
		AU 5882796 A	18-12-1996